

10 APPARATUS AND METHOD
FOR FLOW ELECTROPORATION
OF BIOLOGICAL SAMPLES

15 FIELD OF THE INVENTION

15 The present invention relates to methods and apparatus for the encapsulation of biologically-active substances in various cell populations. More particularly, the present invention relates to a method and apparatus for the encapsulation of biologically-active substances in various cell populations in blood by electroporation to 20 achieve therapeutically desirable changes in the physical characteristics of the various cell populations in blood.

DESCRIPTION OF THE RELATED ART

25 *Red blood cells*

In the vascular system of an adult human being, blood has a volume of about 5 to 6 liters. Approximately one half of this volume is occupied by cells, including red blood cells (erythrocytes), white blood cells (leukocytes), and blood platelets. Red blood cells 30 comprise the majority of the cellular components of blood. Plasma,

the liquid portion of blood, is approximately 90 percent water and 10 percent various solutes. These solutes include plasma proteins, organic metabolites and waste products, and inorganic compounds.

The major function of red blood cells is to transport

5 oxygen from the lungs to the tissues of the body, and transport carbon dioxide from the tissues to the lungs for removal. Very little oxygen is transported by the blood plasma because oxygen is only sparingly soluble in aqueous solutions. Most of the oxygen carried by the blood is transported by the hemoglobin of the erythrocytes.

10 Erythrocytes in mammals do not contain nuclei, mitochondria or any other intracellular organelles, and they do not use oxygen in their own metabolism. Red blood cells contain about 35 percent by weight hemoglobin, which is responsible for binding and transporting oxygen.

15 Hemoglobin is a protein having a molecular weight of approximately 64,500 daltons. It contains four polypeptide chains and four heme prosthetic groups in which iron atoms are bound in the ferrous state. Normal globin, the protein portion of the hemoglobin molecule, consists of two α chains and two β chains.

20 Each of the four chains has a characteristic tertiary structure in which the chain is folded. The four polypeptide chains fit together in an approximately tetrahedral arrangement, to constitute the characteristic quaternary structure of hemoglobin. There is one heme group bound to each polypeptide chain which can reversibly bind

25 one molecule of molecular oxygen. When hemoglobin combines with oxygen, oxyhemoglobin is formed. When oxygen is released, the oxyhemoglobin is reduced to deoxyhemoglobin.

Although the secondary and tertiary structure of various hemoglobin subunits are similar, reflecting extensive homology in amino acid composition, the variations in amino acid composition that do exist impart marked differences in hemoglobin's oxygen carrying properties. In addition, the quaternary structure of hemoglobin leads to physiologically important allosteric interactions between the subunits, a property lacking in monomeric myoglobin which is otherwise very similar to the α -subunit of hemoglobin.

Comparison of the oxygen binding properties of myoglobin and hemoglobin illustrate the allosteric properties of hemoglobin that results from its quaternary structure and differentiate hemoglobin's oxygen binding properties from that of myoglobin. The curve of oxygen binding to hemoglobin is sigmoidal typical of allosteric proteins in which the substrate, in this case oxygen, is a positive homotropic effector. When oxygen binds to the first subunit, of deoxyhemoglobin, it increases the affinity of the remaining subunits for oxygen. As additional oxygen is bound to the second and third subunits, oxygen binding is further, incrementally, strengthened, so that at the oxygen tension in lung alveoli, hemoglobin is fully saturated with oxygen. As oxyhemoglobin circulates to deoxygenated tissue, oxygen is incrementally unloaded and the affinity of hemoglobin for oxygen is reduced. Thus at the lowest oxygen tensions found in very active tissues the binding affinity of hemoglobin for oxygen is very low allowing maximal delivery of oxygen to the tissue. In contrast the oxygen binding curve for myoglobin is hyperbolic in character indicating the absence of allosteric interactions in this process. When the affinity for oxygen

is increased, the sigmoidal curve is shifted to the right. This shift of the curve is commonly known as a "right shift".

The allosteric oxygen binding properties of hemoglobin arise directly from the interaction of oxygen with the iron atom of the heme prosthetic groups and the resultant effects of these interactions on the quaternary structure of the protein. When oxygen binds to an iron atom of deoxyhemoglobin it pulls the iron atom into the plane of the heme. Since the iron is also bound to histidine F8, this residue is also pulled toward the plane of the heme ring. The conformational change at histidine F8 is transmitted throughout the peptide backbone resulting in a significant change in tertiary structure of the entire subunit. Conformational changes at the subunit surface lead to a new set of binding interactions between adjacent subunits. The latter changes include disruption of salt bridges and formation of new hydrogen bonds and new hydrophobic interactions, all of which contribute to the new quaternary structure.

The latter changes in subunit interaction are transmitted, from the surface, to the heme binding pocket of a second deoxy subunit and result in easier access of oxygen to the iron atom of the second heme and thus a greater affinity of the hemoglobin molecule for a second oxygen molecule. The tertiary configuration of low affinity, deoxygenated hemoglobin (Hb) is known as the taut (T) state. Conversely, the quaternary structure of the fully oxygenated high affinity form of hemoglobin (HbO_2) is known as the relaxed (R) state.

Delivery of oxygen to tissues depends upon a number of factors including, but not limited to, the volume of blood flow, the

number of red blood cells, the concentration of hemoglobin in the red blood cells, the oxygen affinity of the hemoglobin and, in certain species, on the molar ratio of intra-erythrocytic hemoglobins with high and low oxygen affinity. The oxygen affinity of hemoglobin 5 depends on four factors as well, namely: (1) the partial pressure of oxygen; (2) the pH; (3) the concentration of the allosteric effector 2,3-diphosphoglycerate (DPG) in the hemoglobin; and (4) the concentration of carbon dioxide. In the lungs, at an oxygen partial 10 pressure of 100 mm Hg, approximately 98% of circulating hemoglobin is saturated with oxygen. This represents the total oxygen transport capacity of the blood. When fully oxygenated, 100 mL of whole mammalian blood can carry about 21 mL of gaseous oxygen.

The effect of the partial pressure of oxygen and the pH 15 on the ability of hemoglobin to bind oxygen is best illustrated by examination of the oxygen saturation curve of hemoglobin. An oxygen saturation curve plots the percentage of total oxygen-binding sites of a hemoglobin molecule that are occupied by oxygen molecules when solutions of the hemoglobin molecule are in 20 equilibrium with different partial pressures of oxygen in the gas phase.

As stated above, the oxygen saturation curve for hemoglobin is sigmoid. Thus, binding the first molecule of oxygen increases the affinity of the remaining hemoglobin for binding 25 additional oxygen molecules. As the partial pressure of oxygen is increased, a plateau is approached at which each of the hemoglobin

molecules is saturated and contains the upper limit of four molecules of oxygen.

The reversible binding of oxygen by hemoglobin is accompanied by the release of protons, according to the equation:

5



Thus, an increase in the pH will pull the equilibrium to the right and cause hemoglobin to bind more oxygen at a given partial pressure. A 10 decrease in the pH will decrease the amount of oxygen bound.

In the lungs, the partial pressure of oxygen in the air spaces is approximately 90 to 100 mm Hg and the pH is also high relative to normal blood pH (up to 7.6). Therefore, hemoglobin will tend to become almost maximally saturated with oxygen in the lungs.

15 At that pressure and pH, hemoglobin is approximately 98 percent saturated with oxygen. On the other hand, in the capillaries in the interior of the peripheral tissues, the partial pressure of oxygen is only about 25 to 40 mm Hg and the pH is also relatively low (about 7.2 to 7.3). Because muscle cells use oxygen at a high rate thereby 20 lowering the local concentration of oxygen, the release of some of the bound oxygen to the tissue is favored. As the blood passes through the capillaries in the muscles, oxygen will be released from the nearly saturated hemoglobin in the red blood cells into the blood plasma and thence into the muscle cells. Hemoglobin will release 25 about a third of its bound oxygen as it passes through the muscle capillaries, so that when it leaves the muscle, it will be only about 64 percent saturated. In general, the hemoglobin in the venous blood

leaving the tissue cycles between about 65 and 97 percent saturation with oxygen in its repeated circuits between the lungs and the peripheral tissues. Thus, oxygen partial pressure and pH function together to effect the release of oxygen by hemoglobin

5 A third important factor in regulating the degree of oxygenation of hemoglobin is the allosteric effector 2,3-diphosphoglycerate (DPG). DPG is the normal physiological effector of hemoglobin in mammalian erythrocytes. DPG regulates the oxygen-binding affinity of hemoglobin in the red blood cells in
10 relationship to the oxygen partial pressure in the lungs. In general, the higher the concentration of DPG in the cell, the lower the affinity of hemoglobin for oxygen.

When the delivery of oxygen to the tissues is chronically reduced, the concentration of DPG in the erythrocytes is
15 increased in normal individuals. For example, at high altitudes the partial pressure of oxygen is significantly less. Correspondingly, the partial pressure of oxygen in the tissues is less. Within a few hours after a normal human subject moves to a higher altitude, the DPG level in the red blood cells increases, causing more DPG to be bound
20 and the oxygen affinity of the hemoglobin to decrease. Increases in the DPG level of red blood cells also occur in patients suffering from hypoxia. This adjustment allows the hemoglobin to release its bound oxygen more readily to the tissues to compensate for the decreased oxygenation of hemoglobin in the lungs.

25 As normally isolated from blood, hemoglobin contains a considerable amount of DPG. When hemoglobin is "stripped" of its DPG, it shows a much higher affinity for oxygen. When DPG is

increased, the oxygen binding affinity of hemoglobin decreases. A physiologic allosteric effector such as DPG is therefore essential for the normal release of oxygen from hemoglobin in the tissues.

While DPG is the normal physiologic effector of hemoglobin in mammalian red blood cells, phosphorylated inositol 5 are found to play a similar role in the erythrocytes of some birds and reptiles. Although IHP is unable to pass through the mammalian erythrocyte membrane, it is capable of combining with hemoglobin 10 of mammalian red blood cells at the binding site of DPG to modify the allosteric conformation of hemoglobin, the effect of which is to reduce the affinity of hemoglobin for oxygen. For example, DPG 15 can be replaced by inositol hexaphosphate (IHP), which is even more potent than DPG in reducing the oxygen affinity of hemoglobin. IHP has a 1000-fold higher affinity to hemoglobin than DPG (R.E. Benesch et al., *Biochemistry*, Vol. 16, pages 2594-2597 (1977)) and increases the P50 of hemoglobin up to values of 96.4 mm Hg at pH 7.4, and 37° C (*J. Biol. Chem.*, Vol. 250, pages 7093-7098 (1975)).

The oxygen release capacity of mammalian red blood cells can be enhanced by introducing certain allosteric effectors of hemoglobin into erythrocytes, thereby decreasing the affinity of hemoglobin for oxygen and improving the oxygen economy of the blood. This phenomenon suggests various medical applications for 20 treating individuals who are experiencing lowered oxygenation of their tissues due to the inadequate function of their lungs or 25 circulatory system.

Because of the potential medical benefits to be achieved from the use of these modified erythrocytes, various techniques have

been developed in the prior art to enable the encapsulation of allosteric effectors of hemoglobin in erythrocytes. Accordingly, numerous devices have been designed to assist or simplify the encapsulation procedure. The encapsulation methods known in the 5 art include osmotic pulse (swelling) and reconstitution of cells, controlled lysis and resealing, incorporation of liposomes, and electroporation. Current methods of electroporation make the procedure commercially impractical on a scale suitable for commercial use.

10 The following references describe the incorporation of polyphosphates into red blood cells by the interaction of liposomes loaded with IHP: *Gersonde, et al.*, "Modification of the Oxygen Affinity of Intracellular Haemoglobin by Incorporation of Polyphosphates into Intact Red Blood Cells and Enhanced O₂ 15 Release in the Capillary System", *Biblthca. Haemat.*, No. 46, pp. 81-92 (1980); *Gersonde, et al.*, "Enhancement of the O₂ Release Capacity and of the Bohr-Effect of Human Red Blood Cells after Incorporation of Inositol Hexaphosphate by Fusion with Effector-Containing Lipid Vesicles", *Origins of Cooperative Binding of 20 Hemoglobin*, (1982); and *Weiner*, "Right Shifting of Hb-O₂ Dissociation in Viable Red blood cells by Liposomal Technique," *Biology of the Cell*, Vol. 47, (1983).

25 Additionally, U.S. Patent Nos. 4,192,869, 4,321,259, and 4,473,563 to *Nicolau et al.* describe a method whereby fluid-charged lipid vesicles are fused with erythrocyte membranes, depositing their contents into the red blood cells. In this manner, it is possible to transport allosteric effectors such as inositol

hexaphosphate into erythrocytes, where, due to its much higher binding constant, IHP replaces DPG at its binding site in hemoglobin.

In accordance with the liposome technique, IHP is dissolved in a phosphate buffer until the solution is saturated and a mixture of lipid vesicles is suspended in the solution. The suspension is then subjected to ultrasonic treatment or an injection process, and then centrifuged. The upper suspension contains small lipid vesicles containing IHP, which are then collected. Erythrocytes are added to the collected suspension and incubated, during which time the lipid vesicles containing IHP fuse with the cell membranes of the erythrocytes, thereby depositing their contents into the interior of the erythrocyte. The modified erythrocytes are then washed and added to plasma to complete the product.

The drawbacks associated with the liposomal technique include poor reproducibility of the IHP concentrations incorporated in the red blood cells and significant hemolysis of the red blood cells following treatment. Additionally, commercialization is not practical because the procedure is tedious and complicated.

In an attempt to solve the drawbacks associated with the liposomal technique, a method of lysing and the resealing red blood cells was developed. This method is described in the following publication: *Nicolau, et al.*, "Incorporation of Allosteric Effectors of Hemoglobin in Red Blood Cells. Physiologic Effects," *Bibliotheca Haemat.*, No. 51, pp. 92-107, (1985). Related U.S. Patent Nos. 4,752,586 and 4,652,449 to *Ropars et al.* also describe a procedure of encapsulating substances having biological activity in human or

animal erythrocytes by controlled lysis and resealing of the erythrocytes, which avoids the RBC-liposome interactions.

The technique is best characterized as a continuous flow dialysis system which functions in a manner similar to the osmotic pulse technique. Specifically, the primary compartment of at least one dialysis element is continuously supplied with an aqueous suspension of erythrocytes while the secondary compartment of the dialysis element contains an aqueous solution which is hypotonic with respect to the erythrocyte suspension. The hypotonic solution causes the erythrocytes to lyse. The erythrocyte lysate is then contacted with the biologically active substance to be incorporated into the erythrocyte. To reseal the membranes of the erythrocytes, the osmotic and/or oncotic pressure of the erythrocyte lysate is increased and the suspension of resealed erythrocytes is recovered.

In related U.S. Patent Nos. 4,874,690 and 5,043,261 to *Goodrich et al.*, a related technique involving lyophilization and reconstitution of red blood cells is disclosed. As part of the process of reconstituting the red blood cells, the addition of various polyanions, including inositol hexaphosphate, is described. Treatment of the red blood cells according to the process disclosed results in a cell with unaffected activity. Presumably, the IHP is incorporated into the cell during the reconstitution process, thereby maintaining the activity of the hemoglobin.

In U.S. Patent Nos. 4,478,824 and 4,931,276 to *Franco et al.*, a second related method and apparatus is described for introducing effective agents, including inositol hexaphosphate, into mammalian red blood cells by effectively lysing and resealing the

cells. The procedure is described as the "osmotic pulse technique." In practicing the osmotic pulse technique, a supply of packed red blood cells is suspended and incubated in a solution containing a compound which readily diffuses into and out of the cells, the 5 concentration of the compound being sufficient to cause diffusion thereof into the cells so that the contents of the cells become hypertonic. Next, a trans-membrane ionic gradient is created by diluting the solution containing the hypertonic cells with an essentially isotonic aqueous medium in the presence of at least one 10 desired agent to be introduced, thereby causing diffusion of water into the cells with a consequent swelling and an increase in permeability of the outer membranes of the cells. This "osmotic pulse" causes the diffusion of water into the cells and a resultant swelling of the cells which increase the permeability of the outer cell 15 membrane to the desired agent. The increase in permeability of the membrane is maintained for a period of time sufficient only to permit transport of least one agent into the cells and diffusion of the compound out of the cells.

Polyanions which may be used in practicing the osmotic 20 pulse technique include pyrophosphate, tripolyphosphate, phosphorylated inositol, 2,3-diphosphoglycerate (DPG), adenosine triphosphate, heparin, and polycarboxylic acids which are water-soluble, and non-disruptive to the lipid outer bilayer membranes of red blood cells.

25 The osmotic pulse technique has several shortcomings including the fact that the technique is tedious, complicated and

unsuited to automation. For these reasons, the osmotic pulse technique has had little commercial success.

Another method for encapsulating various biologically-active substances in erythrocytes is electroporation. Electroporation 5 has been used for encapsulation of foreign molecules in different cell types including IHP red blood cells as described in *Mouneimne, et al.*, "Stable rightward shifts of the oxyhemoglobin dissociation curve induced by encapsulation of inositol hexaphosphate in red blood cells using electroporation," FEBS, Vol. 275, No. 1, 2, pp. 117-120 10 (1990).

The process of electroporation involves the formation of pores in the cell membranes, or in any vesicles, by the application of electric field pulses across a liquid cell suspension containing the cells or vesicles. During the poration process, cells are suspended in 15 a liquid media and then subjected to an electric field pulse. The medium may be electrolyte, non-electrolyte, or a mixture of electrolytes and non-electrolytes. The strength of the electric field applied to the suspension and the length of the pulse (the time that the electric field is applied to a cell suspension) varies according to 20 the cell type. To create a pore in a cell's outer membrane, the electric field must be applied for such a length of time and at such a voltage as to create a set potential across the cell membrane for a period of time long enough to create a pore.

Four phenomenon appear to play a role in the process of 25 electroporation. The first is the phenomenon of dielectric breakdown. Dielectric breakdown refers to the ability of a high electric field to create a small pore or hole in a cell membrane. Once

a pore is created, a cell can be loaded with a biologically-active substances. The second phenomenon is the dielectric bunching effect, which refers to the mutual self attraction produced by the placement of vesicles in a uniform electric field. The third 5 phenomenon is that of vesicle fusion. Vesicle fusion refers to the tendency of membranes of biological vesicles, which have had pores formed by dielectric breakdowns, to couple together at their mutual dialectic breakdown sites when they are in close proximity. The fourth phenomenon is the tendency of cells to line up along one of 10 their axes in the presence of high frequency electric fields. Thus, electroporation relates to the use in vesicle rotational prealignment, vesicle bunching and dielectric constant or vesicles for the purpose of loading and unloading the cell vesicle.

15 Electroporation has been used effectively to incorporate allosteric effectors of hemoglobin in erythrocytes. In the article by *Mouneime, et al.*, supra, it was reported that right shifts of the hemoglobin-oxygen dissociation in treated erythrocytes having incorporated IHP can be achieved. Measurements at 24 and 48 hours after loading with IHP showed a stable P50 value indicating that 20 resealing of the erythrocytes was permanent. Furthermore, it was shown that red blood cells loaded with inositol hexaphosphate have a normal half life of eleven days. However, the results obtained by *Mouneimne* and his colleagues indicate that approximately 20% of the re-transfused cells were lost within the first 24 hours of 25 transfusion. U.S. Patent Nos. 5,720,921, 6,090,617, and 6,074,605 are incorporated herein by reference in their entirety and all disclose an apparatus and method for flow electroporation.

The electroporation methods disclosed in the prior art are not suitable for processing large volumes of sample, nor use of a high or repetitive electric charge. In addition, the stability of the P_{50} right shift as well as the stability of the red blood cells has not 5 proved adequate for clinical use. Furthermore, the methods are not suitable for use in a continuous or "flow" electroporation chamber. Available electroporation chambers are designed for static use only; namely, processing of samples by batch. Continuous use of a "static" chamber results in over heating of the chamber and increased 10 cell lysis. Furthermore, the existing technology is unable to incorporate a sufficient quantity of IHP in a sufficient percentage of the cells being processed to dramatically change the oxygen carrying capacity of the blood. In addition, the prior art methods require elaborate equipment and are not suited for loading red blood cells of 15 a patient at the point of care. Thus, the procedure is time consuming and not suitable for use on a commercial scale.

What is needed is a simple, efficient and rapid method for encapsulating biologically-active substances in erythrocytes in sufficient volume while preserving the integrity and biologic 20 function of the cells. The potential therapeutic applications of biologically altered blood cells suggests the need for simpler, and more effective and complete methods of encapsulation of biologically-active substances, including allosteric effectors of hemoglobin in intact erythrocytes.

25 There are numerous clinical conditions that would benefit from treatments that would increase of oxygen bound to hemoglobin. For example to tissue, the leading cause of death in the

United States today is cardiovascular disease. The acute symptoms and pathology of many cardiovascular diseases, including congestive heart failure, ischemia, myocardial infarction, stroke, intermittent claudication, and sickle cell anemia, result from an insufficient supply of oxygen in fluids that bathe the tissues. Likewise, the acute loss of blood following hemorrhage, traumatic injury, or surgery results in decreased oxygen supply to vital organs. Without oxygen, tissues at sites distal to the heart, and even the heart itself, cannot produce enough energy to sustain their normal functions. The result of oxygen deprivation is tissue death and organ failure. Another area that would benefit from treatments that would increase delivery of oxygen bound to hemoglobin to tissue is racing animals, athletes, etc.

Another area is in treating diseases such as adult respiratory distress syndrome because administration of blood that is capable of increased delivery of oxygen to the peripheral tissues will ease the pressure of loading hemoglobin in the lungs.

Although the attention of the American public has long been focused on the preventive measures required to alleviate heart disease, such as exercise, appropriate dietary habits, and moderation in alcohol consumption, deaths continue to occur at an alarming rate. One approach to alleviate the life-threatening consequences of cardiovascular disease is to increase oxygenation of tissues during acute stress. The same approach is also appropriate for persons suffering from blood loss or chronic hypoxic disorders, such as congestive heart failure.

Another condition which could benefit from an increase in the delivery of oxygen to the tissues is anemia. A significant portion of hospital patients experience anemia or a low "crit" caused by an insufficient quantity of red blood cells or hemoglobin in their 5 blood. This leads to inadequate oxygenation of their tissues and subsequent complications. Typically, a physician believes that he or she can temporarily correct this condition by transfusing the patient with units of packed red blood cells.

Enhanced blood oxygenation may also reduce the 10 number of heterologous transfusions and allow use of autologous transfusions in more cases. The current method for treatment of anemia or replacement of blood loss is transfusion of whole human blood. It is estimated that three to four million patients receive 15 transfusions in the U.S. each year for surgical or medical needs. In situations where there is more time or where the religious beliefs of the patient forbid the use of heterologous blood for transfusions, it is advantageous to completely avoid the use of donor or heterologous blood and instead use autologous blood.

Often the amount of blood which can be drawn and 20 stored prior to surgery limits the use of autologous blood. Typically, a surgical patient does not have enough time to donate a sufficient quantity of blood prior to surgery. A surgeon would like to have several units of blood available. As each unit requires a period of several weeks between donations and can not be done less than two 25 weeks prior to surgery, it is often impossible to sequester an adequate supply of blood. By processing autologous blood with

IHP, less blood is required and it becomes possible to completely avoid the transfusion of heterologous blood.

As IHP-treated red blood cells transport 2-3 times as much oxygen as untreated red blood cells, in many cases, a physician 5 will need to transfuse fewer units of IHP-treated red blood cells. This exposes the patient to less heterologous blood, decreases the extent of exposure to viral diseases from blood donors and minimizes immune function disturbances secondary to transfusions. The ability to infuse more efficient red blood cells is also 10 advantageous when the patient's blood volume is excessive. In other more severe cases, where oxygen transport is failing, the ability to rapidly improve a patient's tissue oxygenation is life saving.

Although it is evident that methods of enhancing oxygen delivery to tissues have potential medical applications, 15 currently there are no methods clinically available for increasing tissue delivery of oxygen bound to hemoglobin. Transient elevations of oxygen deposition (6 to 12 hours) have been described in experimental animals using either DPG or molecules that are precursors of DPG. The natural regulation of DPG synthesis *in vivo* 20 and its relatively short biological half-life, however, limit the DPG concentration and the duration of increased tissue PO₂, and thus limit its therapeutic usefulness.

What is needed is a simple, efficient and rapid method 25 for encapsulating biologically-active substances, such as IHP, in erythrocytes without damaging the erythrocytes beyond their ability to produce a clinical effect. An important requirement for any system of introducing IHP into red blood cells is that the right shift

of the sigmoidal oxygen binding curve be substantially stable and the red blood cell must be substantially similar to untreated red blood cells.

5 *Gene transfection*

Efforts to develop human gene therapies have their roots in the 1950s, when early successes with kidney transplantation led to speculation that it might be possible to transplant cells from a normal individual into a patient suffering from a genetic disease. Soon after 10 the discovery of the enzymatic defects in Gaucher's and Niemann-Pick disease, scientists considered organ and bone marrow transplantation and enzyme supplementation to treat rare genetic disorders (Brady, R., NEJM 275:312 (1966)). By the late 1960s and early 1970s, several investigators speculated that it also might be 15 possible to introduce genes into a patient's own cells, and the cloning of the first human genes only a few years later intensified work in the field.

Until recently, almost all of the theoretical and experimental work on human gene therapy was centered on 20 extremely rare genetic diseases, and gene therapy has come to mean, to many in the field, the modification of a patient's genes to treat a genetic disease. However, gene therapy has far wider applications than simply treatment of a genetic disease. Gene therapy is perhaps more appropriately described as medical intervention in which cells, 25 either from the individual to be treated or another appropriate source, are modified genetically to treat or cure any condition, regardless of etiology, that will be ameliorated by the long-term delivery of a

therapeutic protein. Gene therapy can therefore be thought of as an *in vivo* protein production and delivery system, and almost all diseases that are currently treated by the administration of proteins are candidates for treatment using gene therapy.

5 Gene therapy can be divided into two areas: germ cell and somatic cell gene therapy. Germ cell gene therapy refers to the modification of sperm cells, egg cells, zygotes, or early stage embryos. On the basis of both ethical and practical criteria, germ cell gene therapy is inappropriate for human use. In contrast to germ cell
10 gene therapy, somatic cell gene therapy would affect only the person under treatment (somatic cells are cells that are not capable of developing into whole individuals and include all of the body's cells with the exception of the germ cells). As such, somatic cell gene therapy is a reasonable approach to the treatment and cure of certain
15 disorders in human beings.

In conventional somatic cell gene therapy system, somatic cells (e.g., fibroblasts, hepatocytes, or endothelial cells) are removed from the patient, cultured *in vitro*, transfected with the gene(s) of therapeutic interest, characterized, and reintroduced into
20 the patient. The means by which these five steps are carried out are the distinguishing features of a given gene therapy system.

Presently-available approaches to gene therapy include the use of infectious vectors, such as retroviral vectors, which include the genetic material to be expressed. Such approaches have
25 limitations, such as the potential of generating replication-competent viruses during vector production; recombination between the therapeutic virus and endogenous retroviral genomes, potentially

generating infectious agents with novel cell specificities, host ranges, or increased virulence and cytotoxicity; independent integration into large numbers of cells, increasing the risk of a tumorigenic insertional event; limited cloning capacity in the retrovirus (which 5 restricts therapeutic applicability) and short-lived *in vivo* expression of the product of interest. A better approach to providing gene products, particularly one which avoids the risks associated with presently-available methods and provides long-term production, would be valuable.

10 A method for encapsulating genetic material in various cell populations is electroporation. Electroporation has been used for encapsulation of foreign molecules in different cell types including IHP red blood cells as described in *Mouneimne, et al* supra. The electroporation methods disclosed in the prior art are not suitable for 15 processing large volumes of sample, nor use of a high or repetitive electric charge. One of the problems with electroporation of cells has always been the excess heat that occurs during the electroporation process. This heat generated by the electroporation process causes extensive damage to living cells. In addition, the stability of the 20 transformed cells has not proved adequate for clinical use. Furthermore, the methods are not suitable for use in a continuous or “flow” electroporation chamber. Most available electroporation chambers are designed for static use only. Namely, processing of samples by batch. Continuous use of a “static” chamber results in 25 over heating of the chamber and increased cell lysis. Furthermore, the existing technology is unable to incorporate a sufficient quantity of genetic material in a sufficient percentage of the cells being

processed. In addition, the prior art methods require elaborate equipment and are not suited for transforming cells of a patient at the point of care. Thus, the procedure is time consuming and not suitable for use on a commercial scale.

5 *Prior Art Flow Cells*

U.S. Patent No. 5,676,646 discloses a flow electroporation apparatus with a flow cell comprising two electrodes separated by a non-conductive spacer, the spacer defining a flow path. The major problem with this flow cell as well as other prior art 10 flow cells is that the surface area of the electrode is not sufficient to dissipate heat as the cells are being electroporated. Thus, the heat buildup in the prior art flow cells is very large as the cells are being electroporated. This heat build up can cause damage to cells and cell components and decrease the efficiency of the electroporation 15 process.

What is needed is a simple, efficient and rapid method for encapsulating genetic material in cells in sufficient volume in real-time, while preserving the integrity and biologic function of the cells. The potential therapeutic applications of transformed cells 20 suggests the need for simpler, and more effective and complete methods of encapsulation of genetic material in intact cells. In addition, a flow cell is needed that is capable of removing heat so that damage to living cells that are being electroporated is kept to a minimum.

SUMMARY OF THE INVENTION

The present invention relates to a method and apparatus for the encapsulation of biologically-active substances in cell populations. The present invention is particularly suited for cells found in blood and other body fluids. More specifically, the present invention provides an electroporation chamber that may form part of an automated, self-contained, flow apparatus for encapsulating compounds or compositions, such as inositol hexaphosphate, in cells found in blood. More particularly, the present invention also provides a novel flow electroporation cell assembly that is both simple and efficient. 1.

One embodiment of the present inventions is a flow electroporation device comprising walls defining a flow channel configured to receive and to transiently contain a continuous flow of a suspension comprising particles, an inlet flow portal in fluid communication with the flow channel, whereby the suspension can be introduced into the flow channel through the inlet flow portal, an outlet flow portal in fluid communication with the flow channel, whereby the suspension can be withdrawn from the flow channel through the outlet flow portal, the walls defining the flow channel comprising a first electrode plate forming a first wall of the flow channel and a second electrode plate forming a second wall of the flow channel opposite the first wall; wherein the area of the electrodes contact with the suspension, and the distance between the electrodes is chosen so that the thermal resistance of the flow channel is less than approximately 3°C per Watt, the paired electrodes are placed in electrical communication with a source of

electrical energy, whereby an electrical field is formed between the electrodes; whereby the suspension of the particles flowing through the flow channel can be subjected to an electrical field formed between the electrodes.

5 In a specific embodiment, the biologically-active substances are incorporated in red blood cells, thereby reducing the affinity of the hemoglobin for oxygen and enhancing the delivery of oxygen by red blood cells to tissues of a patient. The term "patient" as used here is either a human or an animal. Encapsulation is
10 preferably achieved by electroporation; however, it is contemplated that other methods of encapsulation may be used in practicing the present invention. The method and apparatus, including the electroporation chamber, of the present invention, is equally suited to the encapsulation of a variety of biologically-active substances in
15 various cell populations.

The apparatus and method of the present invention is suited to the incorporation of a variety of biologically-active substances in cells and lipid vesicles. The method, apparatus and chamber of the present invention may be used for introducing a
20 compound or biologically-active substance into a vesicle whether that vesicle is engineered or naturally occurring.

In one embodiment of the present invention, substances or drugs can be introduced into cells or fragments of cells such as platelets. For example, thrombus dissolving substances such as
25 tissue plasminogen activator or streptokinase and the like can be introduced into a population of platelets. These platelets loaded with the thrombus dissolving substances can be then introduced into a

patient who is suffering from a thrombus blocking a blood vessel. The platelet containing the thrombus dissolving substance will then migrate to the site of the thrombus and attach itself to the thrombus. Because the treated platelets contain active thrombus dissolving 5 enzymes, the thrombus is then dissolved. The thrombus dissolving substances can be introduced into the platelets by a variety of methods with the most preferable method being according to the apparatus of the present invention. In another embodiment of the present invention, substances or drugs can be introduced into white 10 cells for the delivery of drugs to the body as a whole or to specific sites within the body. An example of white cells that can be used as delivery vehicles include, but are not limited to, dendritic cells, lymphocytes, macrophages, and the like.

The apparatus, method, and chamber of the present 15 invention may be used to introduce IHP into erythrocytes. The encapsulation of inositol hexaphosphate in red blood cells by electroporation according to the present invention results in a significant decrease in the hemoglobin affinity for oxygen without substantially affecting the life span, ATP levels, K⁺ levels, or normal 20 rheological competence of the cells. In addition, the Bohr effect is not altered except to shift the O₂ binding curve to the right. Lowering the oxygen affinity of the erythrocytes increases the capacity of erythrocytes to dissociate the bound oxygen and thereby improves the oxygen supply to the tissues. Enhancement of the 25 oxygen-release capacity of erythrocytes brings about significant physiological effects, such as a reduction in cardiac output, an

increase in the arteriovenous differences, and improved tissue oxygenation.

The modified erythrocytes prepared in accordance with the present invention, having improved oxygen release capacities, 5 may find their use in situations such as those illustrated below:

1. Under conditions of low oxygen-partial pressure, such as at high altitudes;
2. When the oxygen exchange surface of the lung is reduced, such as occurs in emphysema and adult respiratory distress 10 syndrome;
3. When there is an increased resistance to oxygen diffusion in the lung, such as occurs in pneumonia or asthma;
4. When there is a decrease in the oxygen-transport capacity of erythrocytes, such as occurs with erythropenia or anemia, 15 or when an arteriovenous shunt is used;
5. To treat blood circulation disturbances, such as arteriosclerosis, thromboembolic processes, organ infarct, congestive heart failure, cardiac insufficiency or ischemia;
6. To treat conditions of high oxygen affinity of 20 hemoglobin, such as hemoglobin mutations, chemical modifications of N-terminal amino acids in the hemoglobin-chains, or enzyme defects in erythrocytes;
7. To accelerate detoxification processes by improving oxygen supply;
- 25 8. To decrease the oxygen affinity of conserved blood;

9. To improve the efficacy of various cancer treatments; and

10. To enhance the athletic performance of humans or animals.

5 According to the method and apparatus of the present invention, it is possible to produce modified erythrocytes which contribute to an improved oxygen economy of the blood. These modified erythrocytes are obtained by incorporation of allosteric effectors, such as IHP, by electroporation of the erythrocyte
10 membranes.

The incorporation of the biologically-active substances into the cells in accordance with the method of the present invention, including the encapsulation of allosteric effectors of hemoglobin into erythrocytes, is conducted extracorporeally via an automated, 15 flow electroporation apparatus. Briefly, in one embodiment of the present invention, a cell suspension is introduced into a separation and wash stage of a flow encapsulation apparatus. It is to be understood that cells can be washed by any suitable method known to those of ordinary skill in the art, including but not limited to, 20 centrifugation, filtration, chelation, and osmotic methods. The cells are separated from the suspension, washed and re-suspended in a solution of the biologically-active substance to be introduced into the cell. This suspension is introduced into the electroporation chamber and then incubated. Following electroporation and incubation, the 25 cells are washed and separated. A contamination check is optionally conducted to confirm that all unencapsulated biologically-active

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

substance has been removed. Then, the cells are prepared for storage or reintroduction into a patient.

In accordance with the present invention and with reference to the preferred embodiment, blood is drawn from a 5 patient, the erythrocytes are separated from the drawn blood, the erythrocytes are modified by the incorporation of allosteric effectors and the modified erythrocytes and blood plasma is reconstituted. In this manner, it is possible to prepare and store blood containing IHP-modified erythrocytes.

10 The apparatus of the present invention provides an improved method for the encapsulation of biologically-active substances in cells including an apparatus which is self-contained and therefore sterile, an apparatus which can process large volumes of cells within a shortened time period, an apparatus having 15 improved contamination detection, cooling and incubation elements, an apparatus that is entirely automated and which does not require the active control of a technician once a sample is introduced into the apparatus.

Another embodiment of the present invention is a 20 preparation of red blood cells that has a stable right shifted oxygen dissociation curve. The phrase "stable right shifted blood" as used herein means that the right shifted oxygenation curve remains higher than untreated red blood cells over the same period of time. Untreated freshly drawn red blood cells will have a P_{50} of 25 approximately 27mm Hg. This value decreases over time as it is stored in the blood bank at 2-8°C due to the loss of the allosteric effector 2,3-diphosphoglycerate. After several days in storage the

P_{50} drops to around 22-25 mm Hg. After 1 to 2 weeks the value can drop to around 18-20 mm Hg. It is contemplated as part of the present invention a preparation of isolated red blood cells that have a P_{50} greater than approximately 30 mm Hg. These red blood cells

5 have a stable P_{50} that remains substantially the same over the storage life of the red blood cells or the P_{50} remains substantially above the P_{50} of untreated blood over a period of time. Thus, one embodiment of the present invention is an isolated preparation of red blood cells that can be stored under normal blood bank conditions, e.g., 2-8°C,

10 and has a substantially stable P_{50} of greater than approximately 30 mm Hg, more desirably greater than approximately 35 mm Hg, even more desirably greater than approximately 40 mm Hg, and most desirably greater than approximately 45 mm Hg. It should be noted that depending upon the particular condition that is being treated,

15 more cells with less of an average right shift may be used or fewer cells with a greater average right shift may be used. The present invention of treating red blood cells by flow electroporation with IHP is capable of achieving right shifts greater than approximately 30 mm Hg, more desirably greater than approximately 35 mm Hg,

20 even more desirably greater than approximately 40 mm Hg, and most desirably greater than approximately 45 mm Hg in at least one unit of blood in less than 4 hours. Transfection efficiency can be measured either by the percentage of the cells that express the product of the gene or the secretion level of the product express by

25 the gene.

Another aspect of the present invention is the ability to electroporate cells with minimal cell damage. For example,

according to the present invention, red blood cells can be loaded with IHP by flow electroporation with a minimum of 10% hemolysis. Typically there is 3% to 5% hemolysis immediately after the electroporation process and another 3% to 5% hemolysis in the 5 recovery buffer. After several hours, the rate of hemolysis drops to near zero.

It is further contemplated as part of the present invention that the red blood cells that have a substantially stable elevated P_{50} have been treated with IHP, so that the IHP passes 10 through the red blood cell membrane so that it can bind allosterically to the DPG binding site of hemoglobin. The method of introducing the IHP into the interior of the red blood cell membrane can be by any method that will produce a substantially stable preparation of red blood cells with an elevated P_{50} . For example, the red blood cells can 15 be treated as described herein by flow electroporation in the presence of IHP, or the red blood cells can be exposed to hypo- or hyperosmotic agents, or to membrane solubilizing agents to allow a chemical such as IHP to pass through the red blood cell membrane so that the IHP molecule can bind allosterically to the DPG binding site, 20 thereby replacing the natural DPG in the allosteric binding site on the hemoglobin molecule.

In addition, the red blood cell preparation can be a population of normal, untreated red blood cells that naturally have an elevated P_{50} level. A population of normal, untreated red blood cells 25 that has an elevated P_{50} level can be isolated by density gradient fractionation methods. (See e.g., Bourget, et. al., *Adv. Exp. Med. Biol.*, 1992).

Another embodiment of the present invention includes a method of gene therapy including, but not limited to, the introduction of ribonucleic acid preparations, such as DNA, into live cells. The DNA preparations preferably code for a desired protein and can 5 optionally contain vectors that will facilitate the introduction of the DNA into the genetic mechanisms of the cell and thereby (1) increase the expression of the desired protein; (2) regulate the metabolism of a cell; (3) change the phenotype of a cell or (4) be used as a carrier inside the cell. These methods of adding vectors to 10 naked DNA preparations are well known to those of ordinary skill in the art. The DNA that is introduced using the flow electroporation apparatus of the present invention can be naked DNA or can contain other agents to facilitate entry of the DNA into the cell.

The present invention relates to a method and apparatus 15 for the encapsulation of genetic material in various cell populations found in blood. More specifically, the present invention provides an electroporation chamber that may form part of an automated, self-contained, flow apparatus for encapsulating genetic materials in cells and, more specifically in cells found in blood. In a specific 20 embodiment the genetic material is incorporated in lymphocytes, thereby altering the genetic component of the lymphocytes and transforming the lymphocytes. Encapsulation is preferably achieved by electroporation. The method and apparatus, including the electroporation chamber, of the present invention is equally suited to 25 the encapsulation of genetic material in various cell populations.

The apparatus and method of the present invention is suited to the incorporation of genetic material in cells and lipid

vesicles. The method, apparatus and chamber of the present invention may be used for introducing genetic material into a vesicle whether that vesicle is engineered or naturally occurring. Thus, the present invention includes a method of transfecting a cell comprising 5 providing an expression vector coding for a desired protein or peptide and introducing the expression vector into the cell by flow electroporation.

The incorporation of the genetic material into the cells in accordance with the method of the present invention, including the 10 encapsulation of genetic material into lymphocytes, is conducted extracorporeally via an automated, flow electroporation apparatus. Briefly, a cell suspension is introduced into the separation and wash bowl chamber of the flow encapsulation apparatus. The cells are separated from the suspension, washed and re-suspended in a 15 solution of the genetic material to be introduced into the cell. This suspension is introduced into the electroporation chamber and then incubated. Following electroporation and incubation, the cells are washed and separated. A contamination check is optionally conducted to confirm that all unencapsulated genetic material has 20 been removed. Then, the cells are prepared for storage or reintroduction into a patient. The present invention also includes vaccine wherein an expression vector coding for an antigen is introduced into a cell and the transfected cell is then introduced into a human or animal. The transected cell line expresses the antigen 25 and the body then mounts an immune reaction against the antigen. Optionally, the cell line can be cotransfected with an expression

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

vector that codes for the desired antigen and with a cytokine that will act as an adjuvant thereby enhancing the immune response.

In accordance with the present invention and with reference to the preferred embodiment, blood is drawn from a 5 patient, the lymphocytes are separated from the drawn blood, the lymphocytes are modified by the incorporation of genetic material and the transformed lymphocytes and other components of the blood are reconstituted.

Accordingly, it is an object of the present invention to 10 provide an automated, continuous flow electroporation apparatus.

It is another object of the present invention to provide a continuous flow electroporation device which produces a homogenous population of loaded cells or vesicles.

It is another object of the present invention to provide a 15 sterile and nonpyrogenic method of encapsulating biologically-active substances in cells.

It is another object of the present invention to provided a method and apparatus which results in stable resealing of cells or 20 vesicles following electroporation to minimize lysis of the modified cells or vesicles after electroporation.

It is another object of the present invention to provide a flow electroporation system of the present invention which produces a modified cell population from which all exogenous non-encapsulated biologically-active substances have been removed.

25 It is another object of the present invention to provide a method and apparatus that allows continuous encapsulation of biologically-active substances in a population of cells or vesicles.

It is a further object of the present invention to provide a method and apparatus that achieves the above-defined objects, features, and advantages in a single cycle.

It is a further object of the present invention to provide a 5 method and apparatus that is capable of introducing drugs and substances into platelets.

It is another object of the present invention to provide a continuous flow electroporation chamber.

It is another object of the present invention to provide 10 an improved and more efficient method of encapsulating biologically active substances in cells than those methods currently available.

It is a further object of the present invention to provide a composition suitable for use in the treatment of conditions and/or disease states resulting from a lack of or decrease in oxygenation.

15 Other objects, features, and advantages of the present invention will become apparent upon reading the following detailed description of the preferred embodiment of the invention when taken in conjunction with the drawings and the appended claims.

20 BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a schematic of a high voltage control board layout.

25 Fig. 2 is a schematic diagram of a high voltage system diagram.

Fig. 3 is a schematic diagram system board general layout.

Fig. 4 is a schematic diagram of a pulse modulator and energy reduction modulator board general layout.

Fig. 5 is a picture of the Graphical User Interface During IHP/RBC Preparation.

5 Fig. 6 is a schematic diagram of the Sub Main Start-up Calls (Module 1).

Fig. 7 is a schematic diagram of the Temperature Measurement and Control.

10 Fig. 8 is a schematic diagram of the CAVRO Pump Initialization and Control.

Fig. 9 is a schematic diagram of the Analog Collect and Plot Data.

Fig. 10 is a schematic diagram of the Modulator Pulse Generation.

15 Fig. 11 is an exploded view of one embodiment of the flow cell.

Fig. 12 is a schematic diagram of the disposable unit.

Fig. 13 is an exploded view of the second embodiment of the flow electroporation cell assembly.

20 Fig. 14 is another embodiment of the flow electroporation cell assembly.

Fig. 15 is yet another view of the flow electroporation cell assembly.

25 Fig. 16 is a view of the flow electroporation cell assembly with multiple channels.

Fig. 17 is a view of a non-planar electrode flow cell array.

Fig. 18 is a graph showing the average right shift of the oxygen dissociation curve for several samples of red blood cells that have been electroporated in the presence of IHP.

Fig. 19 is a graph showing the effects of large volume 5 fibroblasts transfected with human erythropoietin (hEPO) gene on the hematocrit of mice.

Fig. 20 is a graph showing electroporation mediated DNA oligo uptake by mammalian cells.

Fig. 21 shows fluorescence difference was observed 10 when β -actin (blue) or scrambled DNA (orange) MBs were incorporated into Jurkat cells by electroporation.

Fig. 22 shows the efficiency of co-transfected cells.

Fig. 23 shows a scatter plot from a flow cytometry measurement of platelets loaded with a marker.

15 Fig. 24 shows functional characteristics of flow electroporated platelets as compared to controls.

Fig. 25. shows in vivo delivery of mIL-12 by cells transfected with IL-12 gene.

Fig. 26. shows inhibition of angiogenesis in implanted 20 Matrigel by cells transfected with IL-12 gene.

DETAILED DESCRIPTION OF THE INVENTION

One embodiment of the present invention provides an automated, self-contained, flow apparatus for encapsulating 25 allosteric compounds or compositions, such as inositol hexaphosphate, in cells or fragments of cells, including, but not limited to, red blood cells, white blood cells, platelets, stem cells,

genetically engineered stem cells, or an expanded population of stem cells. In one embodiment, the apparatus of the present invention combines the features of a plasmaphoresis apparatus with those of a flow electroporation apparatus to form an automated, self-contained 5 flow electroporation device. The present invention further comprises a new flow electroporation chamber that allows use of the chamber under flow rather than static conditions. It is contemplated that the method and apparatus, including the electroporation chamber of the present invention, may be used to encapsulate a variety of 10 biologically-active substances in diverse cell populations.

In one embodiment, the present invention provides a population of modified cells having physical characteristics that make the cells particularly useful for treating conditions which demand or benefit from an increase in the delivery of oxygen to the 15 tissues. In accordance with the method of the present invention, a homogenous population of IHP loaded red blood cells can be obtained with reduced contamination and a reduced propensity to lyse following encapsulation. The treated red blood cells exhibit normal life spans in circulation. Using the present invention, red 20 blood cells of a patient in need of the treatment can be quickly loaded and returned to the patient's circulation.

The method of operation of the apparatus of the present invention is described below with reference to the preferred use of the apparatus, i.e., the encapsulation of allosteric effectors of 25 hemoglobin in red blood cells. Inositol hexaphosphate is the preferred allosteric effector to be used with the present invention. Other sugar phosphates, such as inositol pentaphosphate, inositol

tetraphosphate, inositol triphosphate, inositol diphosphate and diphosphatidyl inositol diphosphate, can also be used. Other suitable allosteric effectors include polyphosphates such as nucleotide triphosphates, nucleotide diphosphates, nucleotide monophosphates, 5 and alcohol phosphate esters. In case of certain mutations of hemoglobin, e.g. "Zurich" hemoglobin, organic anions such as polycarboxylic acids can be used as allosteric effectors. Finally, it is possible to use inorganic anions such as hexacyano ferrate, phosphate or chloride as allosteric effectors.

10 The uses of IHP-treated red blood cells is quite extensive including the treatment of numerous acute and chronic conditions including, but not limited to, hospitalized patients, cardiovascular operations, chronic anemia, anemia following major surgery, coronary infarction and associated problems, chronic 15 pulmonary disease, cardiovascular patients, autologous transfusions, as an enhancement to packed red blood cells transfusion (hemorrhage, traumatic injury, or surgery), congestive heart failure, myocardial infarction (heart attack), stroke, peripheral vascular disease, intermittent claudication, circulatory shock, hemorrhagic 20 shock, anemia and chronic hypoxmia, respiratory alkalemia, metabolic alkalosis, sickle cell anemia, reduced lung capacity caused by pneumonia, surgery, pneumonia, trauma, chest puncture, gangrene, anaerobic infections, blood vessel diseases, such as diabetes, substitute or complement to treatment with hyperbaric 25 pressure chambers, intra-operative red cell salvage, cardiac inadequacy, organ transplant, carbon monoxide, nitric oxide, and cyanide poisoning.

Treating a human or animal for any one or more of the above disease states is done by transfusing into the human or animal between approximately 0.5 and 6 units (1 unit = 453mL \pm 50mL) of IHP-treated blood that has been prepared according to the present 5 invention. In certain cases, there may be a substantially complete replacement of all the normal blood in a patient with IHP-treated blood. The volume of IHP-treated red blood cells that is administered to the human or animal will depend upon the indication being treated. In addition, the volume of IHP-treated red blood cells 10 will also depend upon concentration of IHP-treated red blood cells in the red blood cell suspension. It is to be understood that the quantity of IHP red blood cells that is administered to the patient is not critical and can vary widely and still be effective.

IHP-treated packed red blood cells are similar to normal 15 red blood cells except that the IHP-treated packed red blood cells can deliver 2 to 3 times as much oxygen to tissue per unit of blood when compared to normal, untreated red blood cells. A physician would therefore chose to administer a single unit of IHP-treated packed red blood cells rather than 2 units of the normal red blood cells. IHP- 20 treated packed red blood cells could be prepared in blood processing centers analogously to the present blood processing methods, except for the inclusion of a processing step where the IHP is encapsulated in the cells.

Red blood cells that have been loaded with inositol 25 hexaphosphate according to the present invention can be used to treat a wide variety of diseases and disease states. The IHP loaded red blood cells made according to the present invention can be

administered to a patient undergoing a heart attack thereby increasing the oxygen delivery to the ischemic heart tissue and, at the same time, reducing the cardiac output. The IHP-loaded red blood cells made according to the present invention also can be used to 5 treat any ischemic condition including, but not limited to, "bleeding" anemia, surgical complications, stroke, diabetes, sickle cell disease, burns, intermittent claudication, emphysema, hypothermia, peripheral vascular disease, congestive heart failure, angina, transient ischemic disease, disseminated intravascular coagulation, adult 10 respiratory distress syndrome (ARDS) and cystic fibrosis.

The present invention includes a method of treating a patient in need of tissue oxygenation comprising administering to the patient an effective amount of red blood cells containing a quantity of IHP sufficient to cause a right shift in the oxygen dissociation 15 curve of the hemoglobin associated with the red blood cells. The present invention also includes a method of treating a patient in need of a therapeutic agent comprising administering to the patient an effective amount of red blood cells containing the therapeutic agent.

In one embodiment of the present invention, substances 20 or drugs can be introduced into cells or fragments of cells such as platelets. For example, thrombus dissolving substances such as tissue plasminogen activator, urokinase or streptokinase and the like can be introduced into a population of platelets. Tissue plasminogen activator is sold under the trademark ACTIVASE® by Genentech 25 Corporation, South San Francisco, CA. These platelets loaded with the thrombus dissolving substances can be then introduced into a patient who is suffering from a thrombus blocking a blood vessel.

The platelet containing the thrombus dissolving substance will then migrate to the site of the thrombus and attach itself to the thrombus. Because the treated platelets contain active thrombus dissolving enzymes, the thrombus is then dissolved. It is to be understood that

5 other drugs can be introduced into the platelets or other cells for delivery to damaged tissue. These drugs include, but are not limited to, antibiotics, smooth muscle inhibitors, antifungal agents, antibacterial agents, antiviral agents, chemotherapeutic agents and the like. Antiangiogenic drugs can be incorporated into the platelets.

10 Antiangiogenic drugs include, but are not limited to, AGM-1470 (TNP-470) or antagonists to one of its receptors, MetAP-2; growth factor antagonists, or antibodies to growth factors (including VEGF or bFGF); growth factor receptor antagonists or antibodies to growth factor receptors; inhibitors of metalloproteinases including TIMP,

15 batimastat (BB-94), and marimastat; tyrosine kinase inhibitors including genistein and SU5416; integrin antagonists including antagonists alphaVbeta3/5 or antibodies to integrins; retinoids including retinoic acid or the synthetic retinoid fenretinide; steroids 11 α -epihydrocortisol, corteloxone, tetrahydrocortisone and 17 α -

20 hydroxyprogesterone; protein kinase inhibitors including staurosporine and MDL 27032; vitamin D derivatives including 22-oxa-1 alpha, and 25-dihydroxyvitamin D3; arachidonic acid inhibitors including indomethacin and sulindac; tetracycline derivatives including minocycline; thalidomide derivatives; 2-

25 methoxyestradiol; tumor necrosis factor-alpha; interferon-gamma-inducible protein 10 (IP-10); interleukin 1 and interleukin 12; interferon alpha, beta or gamma; angiostatin protein or plasminogen

fragments; endostatin protein or collagen 18 fragments; proliferin-related protein; group B streptococcus toxin; CM101; CAI; troponin I; squalamine; nitric oxide synthase inhibitors including L-NAME; thrombospondin; wortmannin; amiloride; spironolactone; 5 ursodeoxycholic acid; bufalin; suramin; tecogalan sodium; linoleic acid; captopril; irsogladine; FR-118487; triterpene acids; castanospermine; leukemia inhibitory factor; lavendustin A; platelet factor-4; herbimycin A; diaminoantraquinone; taxol; aurintricarboxylic acid; DS-4152; pentosan polysulphite; radicicol; 10 fragments of human prolactin; erbstatin; eponemycin; shark cartilage; protamine; Louisianin A, C and D; PAF antagonist WEB 2086; auranofin; ascorbic ethers; and sulfated polysaccharide D 4152. The agents, including thrombus dissolving substances, can be introduced into the platelets by a variety of methods with the most 15 preferable method being according to the apparatus of the present invention as described herein.

The present invention also includes a method of treating a patient in need of a therapeutic agent comprising administering to the patient an effective amount of platelets containing the therapeutic 20 agent.

Patients that can be treated with the modified platelets include, but are not limited to, heart attack patients, patients suffering a stroke, and any patient that is suffering from an embolism. The amount of thrombus dissolving substance that is introduced into a 25 platelet is between 0.01 μ g to 1 mg per platelet. Generally speaking, one loads as much thrombus dissolving substance as possible into a population of platelets. The method of introducing the thrombus

dissolving substance into the platelets is similar to the method of introducing IHP into red blood cells as described herein.

The present invention also includes methods and compositions for delivering bioactive compounds to the body by

5 loading red blood cells, white blood cells and/or platelets with agents including, but not limited to, cytokines, such as interferon, colony stimulating factors, and interleukins; hormones, such as growth hormone, insulin, and prolactin; antibodies, including monoclonal antibodies and polyclonal antibodies as well as antibodies conjugated

10 to toxins or radioactive agents, chemotherapeutic agents, such as doxorubicin, amphotericin, and taxol, bioactive peptides, and antiviral agents.

Another embodiment of the present invention is the targeting of therapeutic agents to certain locations in the body by

15 loading a particular cell with a therapeutic agent or agents. Examples of this embodiment include, but are not limited to, loading of platelets with an antiangiogenic agent that will be targeted to a site that has been treated mechanically to remove an atherosclerotic plaque (as in angioplasty) and loading of leukocytes with antibiotics

20 that migrate to a site of an infection.

The present invention includes a method of gene therapy including, but not limited to the introduction of deoxyribonucleic acid and ribonucleic acid preparations into live cells. The DNA and/or RNA preparations preferably code for a

25 desired protein or fragment of a protein and the DNA can optionally contain vectors that will facilitate the introduction of the DNA into the genetic mechanisms of the cell and thereby increase the

expression of the desired protein. These methods of adding vectors to naked DNA preparations are well known to those of ordinary skill in the art. The DNA that is introduced using the flow electroporation apparatus of the present invention can be naked DNA or can contain 5 other agents to facilitate entry of the DNA into the cell.

The present invention can be used to introduce any genetic material into a cell or cell fragment. The genetic material may code for a specific protein or may be an antisense genetic material. Examples of proteins and peptides that can be introduced 10 into human or animal cells by introducing the expression vector that codes for that protein or peptide include, but is not limited to, genes that code for b-cell differentiation factors, b-cell growth factors, mitogenic cytokines, chemotactic cytokines, colony stimulating factors, angiogenesis factors, adhesion factors (cadherins, selectins, 15 integrins, NCAMs, ICAMs, and L1) t-cell replacing factors, differentiation factors, transcription factors, mRNA, heat shock proteins, nuclear protein complexes, and RNA/DNA oligomers. Specific factors that can be introduced into a human or animal using the flow electroporation system of the present invention include, but 20 are not limited to, IFN-alpha, IFN-beta, IFN-omega, IL1, IL2, IL3, IL4, IL5, IL6, IL7, IL8, IL9, IL10, IL11, IL12, IL13, IL14, IL15, IL16, IL17, IL18, leptin, myostatins (growth differentiation factors), macrophage stimulating protein and derivatives thereof, platelet-derived growth factor, tumor necrosis factors (TNF-alpha, TNF-beta, 25 NGF, CD40L, CD137L/4-1BBL, human lymphotoxin-beta, TNF-related apoptosis-inducing ligand (trAIL)), monoclonal antibodies, G-CSF, M-CSF, GM-CSF, PDGF, IL1-alpha, IL1-beta, FGF, IFN-

gamma, IP-10, PF4, GRO, and 9E3, erythropoietin (EPO), endostatin and fragments thereof, angiostatin and fragments thereof, fibroblast growth factors (FGF), VEGF, soluble receptors and any fragments or combinations thereof.

5 The present invention also includes The present invention of transfecting cells by electroporation, preferably flow electroporation, is capable of achieving transfection efficiencies of greater than 40%, preferable greater than 50% and most preferably greater than 60% or 70%. Transfection efficiency can be measured
10 either by the percentage of the cells that express the product of the gene or the secretion level of the product express by the gene. The cells maintain a high viability during and after the electroporation process. Viability is routinely more than 50% or greater.

15 Another advantage of the present invention is the speed at which a large population of cells can be transfected. For example, a population of lymphocytes can be transfected by electroporation by electroporating the sample in less than 5 hours, preferably less than 4 hours and most preferable in less than 3 hours and most preferably in less than 2 hours. The time of electroporation is the time that the
20 sample is processed by the flow electroporation process.

Description of flow electroporation device

The flow electroporation device of the present invention is, in one embodiment, comprised of the following:

25

Instrument (electronics module [power box + tower]);

Computer (communicates with electronics module);

Monitor (displays graphical user interface [GUI] and enables user interaction); and

Disposable Set (component in which flow electroporation of cell suspension occurs.

5

The present invention uses flow electroporation to overcome the limitation of sample size. With this method, a cell suspension is passed across parallel bar electrodes that are contained in a flow cell that is preferably disposable. It is to be understood that 10 different configurations of flow cells can be used in the present invention. For example, see below. During this passage, the cells are subjected to electrical pulses with predetermined characteristics. For example, the specific settings for preparation of IHP-loaded red 15 blood cells are: voltage, 750V; pulse width, 650 μ sec; time between pulses, 100 μ sec; 2 biphasic pulses in a burst; time between bursts, 12 sec; flow rate, 0.05 mL/sec. The molecule of interest (e.g., IHP) then diffuses into the cell following concentration and/or electrical gradients. The present invention is optionally capable of subjecting the cells to a range of electric field strengths.

20

The process is initiated by attaching the flow cell with solutions and cell suspensions in the containers with the necessary fluids and samples. The flow cell snaps into place and is secured by closing a hinged panel. Priming solution (saline) and cell suspension are introduced by providing the required commands to the 25 electroporation system, which controls operation of the pump and pinch valves. As the cells transit the flow path between electrodes, electric pulses of the chosen voltage, duration, and frequency are

applied. Product and waste fluids are collected in the designated containers.

The user inputs the desired voltage and other parameters into the flow electroporation system of the present invention. As 5 noted above, a range of settings is optionally available. The computer communicates to the electronics in the tower to charge the capacitor bank to the desired voltage. Appropriate switches then manipulate the voltage before it is delivered to the flow path to create the electric field (the switches provide alternating pulses or 10 bursts to minimize electrode wear brought on by prolonged exposure to the electric field). The voltage is delivered according to the duration and frequency parameters set into the flow electroporation system of the present invention by the operator. The flow electroporation system of the present invention is now described in 15 detail.

Electronics Module

This section describes how the various components of the electronics module interface with each other in one embodiment 20 of the present invention. Details for all the mechanical and electrical components in the electronics module are included on Tables 1 and 2 below.

Table 1. Mechanical Components

COMPONENT	DESCRIPTION / FUNCTION	MANUFACTURER	PART NUMBER
POWER CABINET ASSY	PLASTIC PANELS THAT HOUSE THE 24 VOLT POWER SUPPLY	NICHOLSON PRECISION INSTRUMENTS (NPI)	1SP0001100AD
TOWER CABINET ASSY	PLASTIC PANELS THAT HOUSE MOST OF THE ELECTRONICS, PUMP, COOLER, HIGH VOLTAGE SUPPLY	NPI	1ST0001200AD
SYSTEM BOARD GUIDE	PLASTIC GUIDE PIECE THAT GUIDES THE PHYSICAL POSITION OF THE SYSTEM BOARD IN THE TOWER ASSY	NPI	1ST0101100PD
SYSTEM BOARD SLIDE	POLYCARBONATE PIECE THAT ENSURES THE SYSTEM BOARD IS LEVEL FOR PROPER CONNECTION	NPI	1ST0101100PD
SYSTEM BOARD SCREW MOUNT	POLYCARBONATE FIXTURES THAT SECURE SYSTEM BOARD TO TOWER	NPI	1ST0301100PD
Mechanical Switch with Bracket	SWITCH THAT WHEN ACTIVATED SIGNALS THE SYSTEM THAT HIGH VOLTAGE PULSES ARE BEING RECEIVED AND RESPONDED	MANUFACTURER: MICRO SWITCH DISTRIBUTOR: MOUSER	1ST0001100PD
DISPENSER + CURRENT MONITOR BRACKET	POLYCARBONATE COMPONENT THAT COLLECTS ANY FLUID THAT MAY DRIP FROM THE PELTIER COOLER, USUALLY IN THE FORM OF CONDENSATION. IT ALSO CONTAINS A CURRENT MONITOR USED FOR DISPLAYING THE CURRENT DRAWN THROUGH THE DISPOSABLE SET	NPI	1ST0201100PD
ALUMINUM FRAME	FRAME FOR THE INSTRUMENT	ITEM PRODUCTS	1ST1001100SA
INFRARED (IR) HOUSING	BLACK DELRON HOUSING THAT HOLDS THE IR DETECTOR AS WELL AS TUBING FOR TEMPERATURE MEASUREMENT	NPI	1ST0320100PD
COMPRESSION PLATE	POLYCARBONATE PLATE THAT COMPRESSES THE DISPOSABLE FLOW CELL TO PREVENT AIR OR FLUID LEAKAGE	NPI	1ST04101100PD
HEAT SINK	ALUMINUM PLATE THAT PROVIDES MEANS FOR REMOVING HEAT FROM HIGH VOLTAGE SWITCHES	NPI	1ST10101100PD
COMPRESSION PLATE LATCHES	LATCHES USED TO LOCK COMPRESSION PLATE ON TO DISPOSABLE FLOW CELL	MCMASTER CARR	1ST08301100PD

Table 2. Electrical Components

COMPONENT	DESCRIPTION	MANUFACTURER PART#	THE RAMED PART#
HIGH VOLTAGE HIGH POWER SUPPLY	DC/DC CONVERTER 125 WATTS AT A MAXIMUM OF 1000V, DESIGNED WITH A FLOATING GROUND FOR SAFETY	ULTRAVOLT MC25-NP125	1ST201100PD
PINCH VALVES	ACTUATED TO OCCLUDE TUBING FROM DISPOSABLE SETS	ASCO/ANGAR 4011A	1ST0201100PD AND 1ST0401100PD
PERISTALTIC PUMP	STEP MOTOR PUSHES FLUID THROUGH DISPOSABLE SET	CALIBRO SI-472443	1ST0401100PD
PELTIER COOLER WITH FAN	REMOVES HEAT FROM DISPOSABLE SET CONTROLLED BY TEMPERATURE SENSOR AND FAN FAN	TB TECHNOLOGIES CF-2061	1ST0401100PD
360 A SWITCHES	CONNECTS HIGH VOLTAGE SYSTEM TO ELECTRODE CONTACT POINTS SOFTWARE CONTROLLED	POWEREX PM4000DSA120	1ST0201100PD
150 A. SWITCHES	HIGH VOLTAGE SYSTEM TO ELECTRODE CONTACT POINTS WHEN ENERGY REDUCTION PULSES ARE USED (SEE GRAPHICAL USER INTERFACE (GUI) SECTION)	POWEREX PM4000DSA120	1ST1001100PD
CURRENT LIMITING RESISTORS	330 Q RESISTOR THAT LIMIT THE AMOUNT OF CURRENT THAT THE HIGH VOLTAGE SYSTEM CAN DELIVER TO THE CAPACITOR BANK	VISHAY DALE 71-RH50-330	1ST0401100PD
ENERGY REDUCTION RESISTORS	1000 Q RESISTOR THAT LIMITS THE AMOUNT OF CURRENT THAT THE HIGH VOLTAGE SYSTEM CAN DELIVER TO THE CAPACITOR BANK BEFORE RAPID DISCHARGE OF CAPACITORS DURING ENERGY REDUCTION PULSES	VISHAY DALE 71-RH50-10K	1ST1001100PD
LOW PASS FILTER	2 U CAPS THAT PREVENT HIGH FREQUENCY HARMONICS FROM EFFECTING HIGH VOLTAGE SWITCHES	CORNELL DUBLIN SCD205K122A325	1ST0501100PD
MINI MEGA PACK	PROVIDES POWER FOR ENTIRE SYSTEM THROUGH TWO BATTERIES, POWER SUPPLIES AND TWO DC/DC CONVERTERS (2 AMPS EACH)	VICOR VM2-14517	1P051100PD
IR SENSOR	INFRARED TEMP SENSOR THAT MONITORS THE FLUID TEMPERATURE EXITING THE FLOW CELL	OMEGA GS35-01-K-80F	1ST0301100PD
INDICATOR LIGHT	ACTIVATES WHEN THE MECHANICAL SWITCH IS ACTIVATED. THIS ALSO SIGNALS THE SYSTEM THAT HIGH VOLTAGE PULSES ARE BEING DELIVERED TO THE DISPOSABLE	DISTRIBUTOR MOUSIR 604-L51T	1T0341100PD
HIGH VOLTAGE CAPACITORS	STORE ENERGY FOR HIGH VOLTAGE PULSES EACH CAP IS RATED FOR 350V AND 1000UF	MALLORY CGH102T350V2L	1ST06101100PD
CURRENT MONITOR	MEASURES CURRENT IN EACH COIL THAT INDUCES CURRENT ON ITS COILS VIA THE MAGNETIC FIELD GENERATED MEASURES THE CURRENT IN TURN RATIO OF 1:2000 PROVIDING A NOMINAL ANALOG OUTPUT CURRENT OF 150 MA	F W BELL CLN-300	1T0711100PD
DC SYSTEM RELAY	PROVIDES GATE FOR AC POWER TO SYSTEM	CRYDOM CR240	1P0521100PD
DC COOLER RELAY	PROVIDES GATE FOR DC POWER TO PELTIER COOLER	CRYDOM DID40	1P0541100PD
DC HIGH VOLTAGE RELAY	PROVIDES GATE FOR POWER TO HIGH VOLTAGE SUPPLY	CRYDOM DID40	1P0551100PD
HIGH VOLTAGE CONTROL BOARD	USES COMPUTER DA VOLTAGE TO CONTROL BOTH HV SUPPLIES AND PROVIDE FOR HV ISOLATION	EMDS/ECA	1E0101100PD
CAPACITOR BOARD	HOLDS HIGH VOLTAGE SWITCHES, CURRENT LIMITING RESISTORS, LOW PASS FILTERS, AND HIGH VOLTAGE CAPS	EMDS	1E0201100PD
ER BOARD	PROVIDES GATE FOR HV WITH ENERGY REDUCTION RESISTORS AND 150 SWITCHES FOR RAPID DISCHARGE OF CAPACITORS. PROVIDES OPTICAL ISOLATION FOR PULSES BETWEEN COMPUTER AND TO HV MODULATOR SWITCHES	EMDS/ECA	1E0301100PD
PULSE MODULATION BOARD	CLOSES CIRCUIT WITH 360 A SWITCHES FOR NORMAL PUMP OF CAPTORS BY ISOLATING HV HIGH VOLTAGE PULSE CREATION, FLUID DETECTOR CONTROL, AND HIGH VOLTAGE SIGNAL MEASUREMENT. CONTAINS OPTICAL ISOLATION CIRCUITY FOR HIGH VOLTAGE SUPPLY AND FLUID DETECTOR. IF HIGH VOLTAGE DIFFERENTIAL > 20V SYSTEM WILL SWEEP	EMDS/ECA	1E0401100PD
SYSTEM BOARD	MAIN CONTROL BOARD FOR FLOW ELECTROPORATION DEVICE (VERSION 1.0) SYSTEM CONTAINS CIRCUITRY FOR HV ISOLATION, HV PULSE CREATION, HV HIGH VOLTAGE PULSE CREATION, FLUID DETECTOR CONTROL, AND HIGH VOLTAGE SIGNAL MEASUREMENT. CONTAINS OPTICAL ISOLATION CIRCUITY FOR HIGH VOLTAGE SUPPLY AND FLUID DETECTOR. IF HIGH VOLTAGE DIFFERENTIAL > 20V SYSTEM WILL SWEEP	EMDS/ECA	1E0501100PD
COMPUTER	DIRECT CONNECTION TO PERISTALTIC PUMP THROUGH RS232 AND SYSTEM CONTROL BOARD THROUGH KPCB104 CABLE FROM KPC1	ICS ADVENT 400-HS	1C0101100PD

COMPONENT	DESCRIPTION	MANUFACTURER PART#	THE RAME PART#
MONITOR	DISPLAYS GUI AND ALLOWS FOR USER INTERFACE AND CONTROL OF GUI PARAMETERS LISTED IN FOLLOWING SECTIONS	DELL 0532U	IC0301100PD
DATA ACQUISITION CARD	INPUT/OUTPUT FROM COMPUTER TO SYSTEM CONTROL BOARD	KEITHLEY KPC-3104	IC0601100PD
ROCKER SWITCH	PROVIDES 24VOLTS TO SYSTEM	MOUNTAIN SWITCH 10DS22	IP0211100PD
TOP FAN	COOLS UNIT	NMB 1725L-05W-B30	IST0301100PD
COOLER PLATINUM SENSOR	PROVIDES TEMPERATURE FEEDBACK TO COMPUTER FROM THE PELTIER COOLER	OMEGA SR7D-1	IST04701100PD

Figures 1-4 provide layouts/diagrams of the high voltage system, system board, and pulse modulator and energy reduction modulator boards. The electronics module can be divided

5 into two parts, the power box and the tower. The module requires a 15A outlet to supply AC power. This power is taken in through the power box and delivered to a 250V/ 10A fuse and an illuminated rocker switch. The “ON” illuminated position of the rocker switch permits the passage of power to the System AC solid-state relay. A

10 relay acts as a gate for the power. The gate can only be opened by the correct logic signal. The correct logic signal here is the “watchdog” signal, which is generated by activation of the FED Version 1.0 software. The watchdog signal was created to circumvent potential hazards to the user from the electronics module

15 in the event the software may not be functioning. Without the watchdog signal, no electronic component in the electronics module will function.

The gated AC power is then converted into DC power and regulated by a Mini MegaPac. Internally, the Mini MegaPAC

20 (Vicor Corporation, Andover, MA) has two isolated 24V power supplies and two 24V power boosters. The two boosters are attached to only one of the 24V isolated supplies. This trio is the power supply that supplies power to the entire system with the exception of

the high voltage power supply. The remaining isolated 24V power supply in the Mini MegaPAC supplies power only to the high voltage power supply in the tower. This separation is an intentional design feature that creates a floating ground for the high voltage 5 pulses, which minimizes potential hazards to the user. The user would have to touch both a point of high voltage and the floating ground to be harmed by the instrument.

With respect to the Mini MegaPAC, power is transferred from the power supplies to the individual electronic components via 10 an umbilical cord connecting the power box to the tower. Two paths of power from the Mini MegaPAC have additional relays. The power to the cooler is gated by software control. Activation of the cooler depends upon the cooler set temperature determined by the user and the corresponding software algorithm used to regulate 15 cooler temperature. The power to the high voltage supply system is gated by the micromechanical switch in the tower, which confirms proper alignment of the disposable set on the instrument. Without a properly attached disposable set, the high voltage system is disabled. The high voltage system is composed of an Ultravolt bipolar high 20 voltage power supply, a capacitor bank ,two 330 ohm current limiting resistors, two 150 A switches, two 300 A switches , two 5 ohm energy reduction resistors, two low pass filters, the capacitor board, and the high voltage control board.

Figures 1 and 2 better illustrate the high voltage system 25 and the components that comprise this system. Fig. 1 is the high voltage control board layout. This board controls and synchronizes the two bipolar 500V voltage supplies that lie within the Ultravolt

high voltage supply. Together the control board and these supplies can produce up to 1000V at alternating polarity. Fig. 2 is an overview of how the pulses are generated by the capacitor bank and manipulated by switches to produce the alternating pulses. The 5 energy reduction switches are also included in this figure. When activated, the energy reduction reduces the charge generated by the capacitors through its own set of resistors and switches. Finally, the manipulated pulses are delivered to the disposable set through low gauge stranded copper wires. To minimize the potential hazard to 10 the user, the entire high voltage system is fed by an isolated power supply to create a floating ground, which is separate from the common ground shared by the rest of the instrument.

The remaining electronics components are fed from the boosted 24V power supply. The pinch valves, tower fan, and pump 15 are activated and initialized when the flow electroporation system of the present invention is on (electronics module and software). This power supply also supplies voltage to the following three printed circuit boards: the pulse modulator board, the energy reduction modulator board, and the system board. The system board is the 20 communication terminal between the computer and the instrument. Fig. 3 displays the general layout of the system board. It is connected to an A/D card in the computer via cable. The system board interfaces with both the high voltage system and the main power supply. The board maintains the isolation between these two 25 systems.

The system board and the computer A/D card in the computer communicate through analog and digital signals. The

system board receives analog signals from components, processes them, and relays the information back to the computer. Signals processed this way are analog inputs. Analog inputs on the system board include the high voltage, current, infrared temperature, and 5 cooler temperature. The transfer of analog information also flows in the opposite direction, which is called analog output. Analog outputs on the system board include the control voltage in the high voltage system, +5V supply, an analog ground, and an A/D trigger. The control voltage in the high voltage system is the signal the computer 10 generates to tell the high voltage system what voltage to attain in order to give the desired output voltage. Any signals related to the high voltage system are optically isolated electronically to preserve the isolation of the high voltage power supply. The A/D trigger is the signal the computer generates to gate the pulses to the desired 15 length.

Digital signals from the computer can be communicated to the instrument via the system board. These signals are processed, manipulated with logic circuitry, and delivered to the electronic component they control. This is known as digital output. Operation 20 of the pinch valves, the watchdog, the cooler, biphasic or monophasic pulses, and the level of energy reduction is under digital output control. This transfer of digital signals can also be sent from the system board to the computer and is known as digital input. The remainder of the system board is logic circuitry used to manipulate 25 the four counter timers available on the computer A/D card to generate the waveforms desired by the user.

The system board also interfaces with the pulse modulator board and the energy reduction modulator board. Both modulator boards contain identical circuitries but are not interchangeable due to incongruent connections between the 5 300 A pulse switches and the 150 A switches. Fig. 4 displays the general layout of the pulse modulator board and energy reduction modulator board. The system board feeds the signal from the generated waveform to the modulator boards. The modulator boards drive the switches to produce the desired waveform.

10 The mechanical framework of the electronics module is primarily polycarbonate, acrylic, and aluminum. Aluminum was chosen based on its weight and ability to transfer heat. Polycarbonate was chosen based on its high strength and easy machinability. Acrylic was used primarily for the drip tray and the shaped base plate 15 for the instrument. Advantages of acrylic are that it is lightweight and that two separate pieces of acrylic can be chemically bonded. It is to be understood that the materials used are not critical to the present invention. The components discussed in the text are listed in Tables 1-5.

20

Computer and Monitor

The main function of the computer and monitor is to enable the user to communicate with the electronics module. Communication is made possible through a data acquisition card in 25 the PCI slot of the computer. The data acquisition card is a Keithley KPCI-3104 containing 16 single-ended analog input channels or 8 differential analog input channels, two 8 bit digital ports

programmable as inputs or outputs, one 7 bit digital I/O programmable port, and four programmable user counter/timers.

The system software and its subsequent versions were created in Visual Basic as a method of communication with the 5 Keithley card. The software contains a Graphical User Interface (GUI) displayed on the monitor, which facilitates the communication between user and electronics module. Traces displaying the voltage and current on the GUI give the user real-time updates on the current run. In addition to communicating through the Keithley card, a 10 communication port (COM port) on the computer is used to communicate with the peristaltic pump in the electronics module via an RS232 port.

The monitor displays the GUI. The GUI presents the various settings used for the flow electroporation process. Table 3 15 below provides an overview of the GUI settings.

Table 3. GUI Settings

Item	Description	Operational Range
High voltage	This entry on the screen establishes the sum of the voltages that are generated by two high voltage supplies connected in series. The software program controls the voltage level of each supply. The "ON" button is used to turn on the GUI. The high voltage supply is returned to zero at the completion of the indicated number of "Pulse Bursts" or the depression of the "OFF" button. The voltage is controlled through an isolated high voltage control board that converts a single analog control voltage from the KPCI-3104 into a pair of complementary control voltages required by the high voltage supplies.	0 – 1000 V
Monophasic / biphasic	Determines whether the pulses in a burst are of the same polarity, or alternating polarity. Internally the system always generates the pulses necessary to provide for biphasic pulses. If the biphasic mode is chosen the biphasic pulses are passed to the high voltage modulator switches. In monophasic mode, one modulator switch is prevented from receiving modulated pulses. The visual basic program controls the flow of pulses through the System Control Board to the high voltage modulator switches.	Option buttons mono or biphasic choice.
First pulse	Determines polarity of first pulse in a burst. The software controls the flow of pulses through the System Control Board by a digital bit in the KPCI-3104. Taken in combination with the previous Monophasic/biphasic option buttons, it is possible to generate a wide set of possible pulse configurations.	Option button Positive or negative choice
Pulse width	Determines width of applied pulses by means of a counter timer located in the KPCI-3104. An integer number determines the pulse width in microseconds. This number is multiplied by the number of cycles of a reference clock to determine the pulse width and the interval between pulses. An internal reference clock on KPCI-3104 operates at 20 MHz, which limits the system to approximately 1600 microseconds for a maximum pulse width including interval between pulses. An external clock is provided to the System Control Board, which operates at 2 MHz thus permitting a 10X multiplier of the total period. The internal reference clock is determined primarily by two parallel banks of the 4X1000pF capacitors in series and buffer conductivity within the disposable set. In monophasic mode the pulse width must be less than the selected time between pulses.	User input 15 μ sec – 6,000 μ sec (using 10X multiplier)
Time between pulses	Determines time between pulses in a burst. In monophasic mode the time between pulses must be greater than the selected pulse width.	15 μ sec – 6,000 μ sec (using 10X multiplier) including pulse width.
Pulses in burst	Determines number of pulses in each burst by input of positive whole numbers. Limitations are based on the number of pulses, time between pulses, and desired pulse width.	User input
Time between bursts	Determines time between each pulse burst. This time interval is developed by a Visual Basic Timer control, which has a time resolution of approximately 20 milliseconds. Limitations are based on time needed to display bursts. As a result the minimum time should be 200 msec with a maximum of 32 sec.	User input 200 msec – 30 sec
ER pulse delay	Determines number of pulses prior to initiating energy reduction pulses. ER pulses are pulses with a short time compared to the normal pulses and thus discharge the capacitors quickly. Note: ER also occurs after last pulse. See Safety Section 8.17.	User input 0 – 10,000 (even numbers)
ER pulse number	Determines number of pulses in each burst that will be delivered at the reduced time constant. See Safety Section 8.17.	User input 0-1000 (even numbers)
PULSE ON	Enables the high voltage power supply and connects the high voltage pulses ON. The OFF button turns the high voltage power off.	User clicks ON
PULSE OFF	Stops the generation of the high voltage pulses and turns the high voltage supply to 0. However, depending on the capacitance of the capacitor bank, additional time must be allowed for the high voltage to discharge to a safe value. Energy reduction mode is activated when OFF has been depressed to more rapidly discharge the capacitors. See Safety Section 8.17.	User clicks OFF
Pulse width/ time between pulses multiplier	Multiples the pulse width and time between pulses value by a factor of 10 if the 10X option is selected. An external clock at 2 MHz is utilized instead of the 20 MHz internal clock.	User input toggle button 1 or 10X
Set temp cooler	Establishes the Peltier cooler temperature. The Visual Basic (VB) program controls this temperature through a digital port in the KPCI-3-104.	User input
Flow rate	Determines the rate at which fluid should be pumped through the system based on the existing tube diameter	Text combo window with pull down menu. 0.005 – 1 mL/sec
Flow direction	Determines the direction that the peristaltic pump should turn, thus determining the direction of fluid flow through the system.	Option buttons CW or CCW
PUMP ON/OFF	Determines whether the pump will be ON or OFF.	ON or OFF – two separate buttons
PRIME START	Actuates certain solenoid pinch valves that allow priming fluid to flow through the flow cell.	User clicks on option button
PRIME END	Actuates certain solenoid pinch valves when the priming process is over.	User clicks on option button
SAMPLE START	Actuates certain solenoid pinch valves when the blood sample is ready for flow electroporation.	User clicks on option button.
OFF	Turns off all pinch valves.	User clicks on option button
Save data	This button is used to activate the data saving form, which allows for data to be saved to a designated disk file. Time, date, voltage, monophasic/biphasic	User clicks on option button

Item	Description	Operational Range
Temperature/voltage calibration	<p>setting, pulse width, time between pulses, clock frequency, IR exit temp, elapsed time, or pulse delay, or pulse number, and up to ten sets of pulse voltage and pulse current displays. One pulse burst is saved every minute for up to a total of ten minutes.</p> <p>This button allows the user to calibrate the cooler, voltage waveforms, and high voltage output. The time is displayed in tenths of seconds. The upper section is used for the calibration of the various temperature measurement channels. For each temperature channel, four values are required. The two-point calibration method uses an independently measured High and Low temperature value along with a corresponding set of digital outputs from the system A/D converter. The digital values can be read by means of the "Digital New Temperature Constants" and current calibration form. These values can be manually inserted in the "Temperature constant" window for the given condition. VB text windows in the lower section of the form contain the current set calibration constants for the non-temperature section of the program. These values can be edited directly as needed. When the "Exit and Save (Calibration Values and Display Constants)" button is depressed all of the current calibration values are passed on to the VB program and stored in the disk calibration file. This form is password-protected.</p>	User click on button

The system software provides the user complete control of all parameters influencing electroporation. The user may only manipulate the high voltage and the set cooler temperature. All other 5 parameters are fixed to the optimized red blood cell (RBC) parameters. Once the run begins, pulsing parameters will freeze and appear dimmer. The remaining enabled controls are pushbuttons to begin and end the pulsing, pump motion, and release of the pinch valves. If the user enters a value for high voltage beyond the 10 capability of the system, the GUI will ask the user to input a number in a given range. The voltage and current traces on the GUI keep the user informed in real time of the waveform being delivered to the sample. These traces also display a cumulative plot of the peak voltages and currents over the period of the run. At the end of the 15 run, the user can chose to save data to a designated location. Plots of this data can be generated to determine the consistency of the waveform the sample was subjected to over the period of the run.

In addition to input parameters and traces, the GUI also displays real time information on the temperature of the cooler, the 20 temperature of the sample, and the time elapsed. The watchdog is continually displayed as a redundant note to the user that the system

is powered. Although the current system lacks an internal diagnostic system, a few simple diagnostics are implemented to increase the awareness of the system. The system can determine if the disposable set is attached properly and will display "Flow Cell Attached" in red text on the GUI when it is attached. Also during pulsing, should the sample reach a temperature that could potentially damage the sample, the system will notify the user via the GUI and discontinue the application of the electric field.

Fig. 8 is a photograph taken of the GUI during an RBC run. The parameters are dimmed and the traces show the conditions the sample is being subjected to. Table 4 below gives a general overview of the described displays.

15 Table 4. GUI Displays

ITEM	DESCRIPTION
Fluid exit temperature	This display shows on the PC monitor shows an unjagged bargraph representing the temperature, in degrees Celsius, as measured by an infrared temperature sensor located on the top of the instrument. When a disposable is attached, the outlet tubing is inserted in the sensor and the display will show the measured temperature. If no disposable is attached, the display will show 0.1 degrees Celsius. Accuracy is approximately +/- 2°C. If the fluid exit temp is between 35-40°C the user will be warned through the GUI by displaying a "Temp is above limit" message. If the temperature exceeds 40°C the same message will be displayed and the high voltage pulsing will stop. If the temperature is between 3°C - 10°C the user will be warned through the GUI by displaying a "Temp is below limit" message. If the temperature falls below 5°C the same message will be displayed and the high voltage pulsing will stop.
Timer display	THIS DISPLAY SHOWS THE TIME THAT HAS ELAPSED SINCE THE LAST TIME THE PULSE ON HIGH VOLTAGE WAS ISSUED. THE TIME IS FORMATTED TO GIVE READINGS EVERY 0.1 SECONDS. The timer display freezes at the current value if the system high voltage pulsing is OFF, or the ON/OFF rocker switch on the system is switched to the OFF position.
Flow cell attached display	This indicator on the GUI labeled "Flow cell attached" signals the user that the flow cell micro-switch has been activated and the high voltage will be supplied whenever the ON button in the pulse parameter section of the GUI is pressed. When the flow cell is attached the text will be red. When the flow cell is not properly attached the display will turn a green color and read "FLOW CELL NOT ATTACHED".
Cooler measured temperature display	This indicator on the GUI displays the actual temperature as measured by the platinum sensor applied to the cooling plate. This sensor is located on the cooling plate. The actual temperature is automatically adjusted via the system controls and Peltier cooler until it equals the set temperature.
Watchdog	This indicator on the GUI displays an alternating alphanumeric display. The display toggles between "0" and "x". The software employs a "WATCHDOG" that generates a square wave signal. With the exception of the external digital logic elements, power is supplied to the system via the high voltage power supply. Should the system experience a software or hardware program crash due to power failure or other reason, the required square wave will not be generated and power to the external circuit including the high voltage supply will be disabled. The watchdog enables the system to properly initialize all of the KPCI-3104 systems prior to the system being powered.
Pulsing notification	The word "PULSING" will appear in red lettering on the GUI when high voltage pulses are being delivered

Flow electroporation system software description

20 The software program employed in the new FES is written in Microsoft Visual Basic (VB), Version 6. The required computer operating system is Microsoft Windows NT, with Service

Pack4 (at a minimum). With the exception of the CAVRO pump, the computer is interfaced to the hardware electronics by means of a Keithley instrument -3104 Data Acquisition and Control card that plugs into a PCI slot in the computer. This interface board allows for

5 analog and digital input and output, as well as counter timers used for computer-controlled pulse generation. Keithley also supplies a VB software driver (DriverLNX). The version of this driver was selected specifically for Windows NT. The computer should operate at least 200 MHz with at least 64 Megabytes of RAM and must have

10 at least one PCI slot.

The CAVRO pump is controlled through a COM port on the computer using a VB command syntax provided by the manufacturer.

Program Overview

15 A fundamental concept of the FES is that system operations, with the exception of an electronics AC power ON/OFF switch, are all controlled from the GUI using mouse clicks and keyboard entries.

20 Due to the high voltages often associated with electroporation, the AC power to the electronics is placed under the control of a watchdog system. The watchdog includes a VB module that generates a continuous series of pulses on one bit of a digital output port. An analog circuit that enables the AC power for the electronics portion of the FES detects these pulses. Since these 25 pulses are only generated by the FES VB program, the AC power is only enabled while the program is running. Should the computer

crash, or the program be stopped for any reason, the AC power to the electronics is terminated.

The VB program is divided into the following five major parts (described in greater detail below): 1) Sub Main Start 5 Up Calls (Module 1); 2) Temperature Measurement and Control; 3) CAVRO Pump Initialization and Control; 4) Modular Pulse Generation; and 5) Analog and Collect Plot Data.

Sub Main Start-up Calls

10 This section of the program begins the process by presetting and computing variables, initializing the KPCI-3104 card and its subsystems, starting the watchdog, and initializing the CAVRO pump.

15 As can be seen in Fig. 6, the sub main calls up a series of sub routines at the beginning of the program as soon as the program is started. The first action is to compute a set of temperature variables. To compute the temperature variables it is necessary to download the appropriate calibration constants from a disk file. The electronics for the system is designed with only one 20 analog control; consequently, the analog voltages need to be scaled for accuracy by means of constants stored on the hard disk of each system. By storing the constants in this manner, it is possible to upgrade the software in many systems with only one version of the code. It is also necessary to preset many of the variables and 25 conditions prior to the start of the main program.

Following this process, a generalized initialization of the KPCI-3104 card is performed, followed by a more specific

initialization of each of the KPCI-3104 subsystems. The shorter subsystem initializations are required any time the Keithley subsystem is used for a different task. The KPCI-3104 card has four different subsystems. Each subsystem is set up as a separate control 5 in VB so that they can be reinitialized separately when their functions are changed. This is particularly important for the Analog Input (AI) subsystem as it is used for collecting pulse trace data at high speed using one set of channels and then reconfigured to collect 10 low speed data for temperature measurements with another set of channels.

Two VB Timers are used in the “Start Up” portion of the program. The first timer, Timer 2 is used to generate the pulses needed for the watchdog signal. This timer runs continuously and with every clock cycle, the digital output (bit(0) of Port(C)), is 15 cycled between a “one” and a “zero”. An analog circuit located in the “Electronics” portion of the system then detects this square wave signal. Upon detection, a TTL level signal is sent to a solid-state relay that controls the 110 V AC power to the “Electronics” portion of the system. A second VB Timer is used to delay the initialization 20 of the CAVRO pump until after the watchdog has completed its task.

Temperature Measurement and Control

This section of the software runs the IR and RTD (temperature control module) temperature measurements. 25 Additionally, the RTD data is used to control the temperature of the thermal cooling system. This part of the program runs continuously; however, the control temperature may be changed through the GUI.

The Temperature Measurement and Control system is depicted in Fig. 7. After the various systems are initialized, VB Timer 5 is enabled. This timer is configured to continuously cycle every five seconds. At the end of each five-second period, it causes

5 the IR temperature to be measured, the cooler temperature to be measured, it starts Timer 6 and then turns on the cooler system. The fraction of the next five-second cycle that the cooler remains on depends upon the difference between the "Desired Cold Temp" and the "Measured Cooler Temp". This system operates continuously

10 while the main program is running.

CAVRO Pump Initialization and Control

This section enables the operator to control the CAVRO pump from the keyboard without involving the KPCI-3104 card. A

15 significant aspect of this section is that the CAVRO pump can only be initialized after the watchdog has had sufficient time to provide power to the pump.

As shown in Fig. 6, the "Start Up Sub Main" module also starts VB Timer 7, which is used to delay the initialization of the

20 CAVRO pump and the COM1 port on the computer. The delay time is sufficient for the watchdog to permit power to the "Electronics". This same power is supplied to the CAVRO pump. The pump requires power to be initialized. The pump is controlled from the keyboard using the COM1 Port.

Modulator Pulse Generation

This section of the program controls the timing of the pulses that are sent to the high voltage modulator switches. The switches allow the designated high voltage to be coupled to the 5 electroporation flow cell.

Fig. 9 consists of a flow chart for the generation of the pulse timing and selection of pulses for the system. The Keithley-3104 card contains four independent Counter Timers (CT). These timers are capable of generating TTL level "Clock" pulses of the 10 proper width and spacing as requested from the keyboard. These pulses are generated continuously until the counter subsystem is reinitialized. CT (3) pulses are used to gate the pulses from CT (0) and CT (1) in "Digital Logic". The timing of the CT (3) gating pulse is determined in software by the number of modulator pulses desired. 15 The fourth and last CT Timer is used to control the timing of an "Energy Reduction" pulse. A second set modulator switches are used to impose a resistive load to rapidly reduce the high voltage during a series of poration pulses. These switches are also used to discharge the capacitor bank when the high voltage is not needed.

20

Analog Collect and Plot Data

This section of the program addresses the synchronized collection of high voltage/current data of the pulses applied to the electroporation flow cell. The data is collected by the A/D converter 25 located on the KPCI-3104 card synchronized with the pulse generation of the CT without interfering with their operation.

In Fig. 10, “bursts” of “modulator pulses” are used to trigger the “analog collect” sub routine. It is important to note that although initiation of the analog data collection of voltage and current pulses in the “Electroporation Flow Cell” are triggered by the 5 modulator pulses, the two subsystems operate independently of each other. The same AI subsystem is employed for both the temperature and modulator pulse measurements. The sub routines controlling each AI function set flags, which prevent interference between the two systems. Prior to the generation of the “burst” of modulator 10 pulses, the AI subsystem is initialized for high-speed data collection. Coincident with the first pulse in the “burst,” the AI subsystem is triggered and data is collected into an array that was established in the AI initialization process. Timer 3 causes a time delay to insure all data is collected into the buffer prior to the plotting of the data on 15 the GUI screen. One set of “Plot Data” is saved in an array every minute for up to twenty minutes. This data may be saved to hard disk if desired at the end of the poration procedure.

Disposable Set

20 The disposable set is composed of PVC bags, PVC tubing, connectors, silicone pump tubing, and a flow cell (see Table 5 below). All plastic components contacting blood are Medical Grade Class VI materials.

Table 5. Components of Disposable Set

DESCRIPTION	MATERIAL	CONTACTS BLOOD PATH	CLASSIFICATION	VENDOR
Electrode gasket	Platinum cured silicone	Yes	USP XXII Class VI	Antron Mold
Electrodes	Iron (Low Carbon Flat Stock - AISI Type C 1018)	No		NPI
Polycarbonate plate	Polycarbonate	Yes	USP XXI Class VI	Medsource Technologies
Polycarbonate retainer	Polycarbonate	No	USP XXI Class VI	Medsource Technologies
Electroplating on electrode surface	100 micronechs pure gold	Yes		AVM Plating
1/4" PVC tubing	PVC	Yes		Baxter
7/8" PVC tubing	PVC	Yes		Baxter
Polycarbonate Y tubing connector	Polycarbonate	Yes	USP Class VI	Value Plastics
Polycarbonate pump tubing connector	Polycarbonate	Yes	USP Class VI	Value Plastics
4" medical grade silicone pump tubing - 0.104" ID X 0.192" OD	Silicone	Yes	USP Class VI	New Age Tech
1" PVC tubing	PVC	Yes		Baxter
15" PVC w/ 150 mL transfer Bag	PVC	Yes		Baxter
16.5" PVC W/ 150 mL transfer Bag	PVC	Yes		Baxter

Fig. 11 illustrates an "exploded" view of the flow cell.

5 The flow cell (also shown in Fig. 15) consists of two low carbon steel (99.9% Iron) electrodes electroplated with approximately 100 pinches of Pure Gold (99.9%). Part of the quality control process specifies that the electrodes are straight to within 77 μ m over their entire length. When the electrodes are placed in parallel, there is a

10 maximum deviation in distance between bar electrodes of 154 μ m. During the Disposable Set assembly process, the electrodes are inserted into the electrode gasket, which is then sandwiched between the retainer and plate. The nominal gap between the parallel bar electrodes is 2 mm. When the disposable set is in use, approximately

15 750 Volts is applied across the electrodes, resulting in an applied electric field of approximately 3.7 kV/cm. Control of electrode

position and straightness dictates that the field strength may vary by only 7.5% or 0.27 kV/cm. The flow cell holds a volume of approximately 1.6 mL.

There are four bags attached to the disposable set (150 mL Baxter Transfer Sets). The first bag is called the *Prime Bag*. This bag contains saline that is pumped from the bag, around the pump, through the flow cell, and into the waste bag. The purpose of the prime bag is to remove air and any particulates that may be in the tubing or flow cell. The second bag, called the *Sample Bag*, contains 10 the cell suspension plus the IHP that will be inserted into the cell via the electroporation process. Each of these bags is connected to PVC tubing lines that pass through designated pinch valves.

The outlet port of the flow cell also has two bags attached, one of which is called the waste bag. This bag holds the 15 priming fluid and a small volume of the sample after they have passed through the flow cell. The last bag is called the product bag, which holds the red blood cells that have been subject to the flow electroporation process with the IHP molecule. Again, there are pinch valves designated for each of these valves to prevent mixing of 20 bag contents.

Alternative Flow Electroporation Cell Assembly

The alternative flow electroporation cell assembly is another embodiment of a flow cell that can be used in the present 25 invention. This embodiment is easy to manufacture and is relatively inexpensive.

Referring now to the figures wherein like reference numerals represent the same or equivalent features throughout the figures, the present invention includes a flow electroporation cell assembly as shown, for instance, in Fig. 13. According to the present 5 invention, selectively fractionated biological units such as blood cells or platelets are introduced from an exterior source into a flow electroporation cell assembly, where the biological units are subjected to electroporation in the presence of a biological or chemical vector, causing the vector to enter transiently opened pores 10 in the encapsulating membranes of the biological units. Once the desired electroporation effect is achieved, the biological units are moved exterior to the flow electroporation cell assembly to permit further handling of the treated units and electroporation of incoming, untreated units. A detailed description of the structure and 15 construction of the flow electroporation cell assembly according to one embodiment of the present invention is provided below.

The present invention is a flow electroporation apparatus for electrical stimulation of suspensions of particles, comprising a flow electroporation cell assembly having one or more 20 inlet flow portals, one or more outlet flow portals, and one or more flow channels, the flow channels being comprised of two or more walls, with the flow channels further being configured to receive and transiently contain a continuous flow of particles in suspension from the inlet flow portals; and paired electrodes disposed in relation to 25 the flow channels such that each electrode forms at least one wall of the flow channels, the electrodes further comprising placing the electrodes in electrical communication with a source of electrical

energy, whereby suspensions of particles flowing through the channels may be subjected to an electrical field formed between the electrodes.

As shown in Fig. 13, a flow electroporation cell assembly **100** may be constructed of two opposing electrode plates **10**. Typically, the electrode plates **10** may be constructed of iron, steel, copper, aluminum, or other electrically conductive metals or metal alloys. The electrode plates **10** may further be coated with gold, platinum, zinc, carbon, or other plating materials to enhance their electrical conductivity. Each electrode plate **10** may be provided with one or more electrical terminals **15** which interface with the power supply circuitry of the overall flow electroporation system. In alternate embodiments, one or both of the opposing electrode plates **10** may further be provided with an interface having a cooling element **20**. The cooling element **20** may be a thermoelectric cooling element, or may provide cooling by direct water or other coolant contact, by ventilation through a heat sink, or other cooling means to dissipate heat generated in the electroporation process, which is typically an exothermic process.

Referring still to Fig. 13, the electrode plates **10** may typically be separated by one or more electrode gap spacers **30**. The thickness of the electrode gap spacers **30** will define and fix a gap **33** between the electrodes **10**. The gap **33** between the electrodes **10** can easily be adjusted to any desired measurement simply by changing the gap spacers **30**. The thickness of one such gap **33** will vary depending on the flow volume and field strength, but will typically be from approximately 0.01 mm to approximately 2 cm, preferably 1

mm to 1 cm, most preferable is 1 to 2 cm. The present invention **BbBbB** The electrode gap spacers **30** are typically constructed of an electrically insulating material, and may be fashioned from such materials as plastic, ceramic, rubber, or other non-conductive 5 polymeric materials or other materials.

Also in another embodiment of the present invention as shown in Fig. 14, a gasket **35** containing a flow channel **40** may be positioned between the electrode plates **10**, with the thickness of the gasket **35** equal to the thickness of the electrode gap spacers **30**. The 10 gasket **35** typically forms a seal with the opposing electrode plates **10**. The gasket **35** may be constructed of silicone, other synthetic or natural rubbers or other polymers, or other electrically non-conductive materials. Integral within the gasket **35**, one or more flow channels **40** is provided. The flow channel **40** is defined by a 15 channel or other cut-out within the gasket **35**. The size and shape of the flow channel **40** is proportional to the size and shape of the electrode plates **10**.

In one embodiment of the flow electroporation cell assembly according to the present invention as shown in Fig. 14, the 20 electrode plates **10** may contain one or more portal bores **45**. Each portal bore **45** may further contain either a flow inlet portal **50** or a flow outlet portal **55**, which serve to connect to and interface with the respective inflow/outflow transport pathways of the overall flow electroporation system.

25 In one embodiment of the flow electroporation cell assembly according to the present invention, the electrode plates **10** and electrode gap spacers **30** may also contain one or more

attachment means to allow their secure assembly. In various embodiments of the present invention, the attachment means **60** may include fasteners such as screws, rivets, rods, or clips which may be employed to secure the desired positions of the electrode plates **10** with the gasket **35** and flow channel **40** interposed therewithin. In still other alternate embodiments of the electroporation flow cell assembly **100** according to the present invention, the attachment means **60** may be secured by adhesives, other bonding techniques, or encapsulation.

In yet another embodiment as shown in Fig. 15, the attachment means **60** may be an attachment bore, sized and positioned to receive bolts **65**. Such bolts **65** may be directly placed through the attachment bores **60**, or may be received within plate bushings **70**, and the bolts may be secured by nuts **75** which serve to secure the flow electroporation cell assembly **100**. In embodiments which employ conductive electrode gap spacers **30**, electrical insulation of the opposing plate electrodes **10** may be achieved by the use of insulating plate bushings **70**.

In various embodiments of the flow electroporation cell assembly according to the present invention, each flow electroporation cell assembly **100** may contain a single flow channel **40** or a plurality of flow channels **40** oriented between the opposing electrode plates **10**, as shown in Fig. 16. When desirable, multiple flow channels **40** may be provided to achieve more rapid, higher volume electroporation treatment.

In an alternate preferred embodiment of the present invention as shown in Fig. 17, a non-planar electrode flow cell array

105 may be used. In an exemplary embodiment, concentric tubular electrodes 110 may be employed. The tubular electrodes typically have concentric insulating spacers 115 utilized to maintain the desired gap space 33. In such an embodiment, the space between the 5 electrodes could also serve as a flow channel 120, with one or more inlet flow portals 125 and outlet flow portals 130 provided either through the outermost tubular electrode wall 135, or through one or both ends of the tubular electrodes 110. In various embodiments according to the present invention, such a tubular electrode flow cell 10 105 could be used singularly, or with a plurality of similar tubular electrode flow cell arrays 105 operating in either parallel or serial function.

15 Preferably, the flow electroporation cell assembly 100 may be provided as a sterile unit for disposable, single-use applications. The components of the flow electroporation cell assembly 100 may thus preferably be constructed of materials capable of withstanding sterilization procedures, such as autoclaving, irradiation, or chemical sterilization.

20 Suitable materials for use in any of the apparatus components as described herein include materials that are biocompatible, approved for medical applications that involve contact with internal body fluids, and should meet US PV1 or ISO 10993 standards. Further the materials will not substantially degrade, from for instance, exposure to the solvents used in the 25 present invention, during at least a single use. The materials are typically sterilizable either by radiation or ethylene oxide (EtO) sterilization. Such suitable materials include materials that are

extrudable if, for instance, used for tubing, and/or injection moldable if, for instance, used for hard containers. Materials useful to form the various components of the apparatus according to the present invention include, but are not limited to, nylon, polypropylene, 5 polycarbonate, acrylic, polysulphone, polyvinylidene fluoride (PVDF), fluoroelastomers such as VITON, available from DuPont Dow Elastomers L.L.C., thermoplastic elastomers such as SANTOPRENE, available from Monsanto, polyurethane, polyvinyl chloride (PVC), polytetrafluoroethylene (PTFE), polyphenylene 10 ether (PFE), perfluoroalkoxy copolymer (PFA) available as TEFLON PFA from E.I. du Pont de Nemours and Company, and combinations thereof.

In many cases it is important to refer to the throughput of 15 electroporation process, or the amount of cell suspension processed in certain amount of time. Since it takes certain amount of energy to electroporate a unit of volume of cell suspension, the more volumetric units is processed in a given time, the more energy in the same time is consumed. Therefore, the speed, or the throughput, of a 20 process can be unequivocally defined as the rate of energy consumption, or power, which is defined as the ratio of energy to time:

$$P = \frac{Q}{t}$$

It can be shown that big amount of heat is normally produced as a side effect of practically every electroporation process, what 25 may cause irreversible damage to biologic material or live cells. Every electric field pulse can cause unwanted warming up of cell suspension by 20-30 degrees Celsius. To avoid or minimize this

effect, cooling is often applied to suspensions of cells being electroporated, especially in the continuous, i.e. flow electroporation processes.

However, while the cooling is usually provided by bringing cell suspension in immediate contact with metal parts which are in their turn being cooled by Peltier elements or by flow of air or fluid, some principal limitations to the cooling process exist. In many cases the designers of electroporation process either neglect or overlook the fact that thermal conductivity of metal is much higher than the 10 one of water (or biological buffer), what means that transfer of heat from the flow channel to the cooling unit is always limited by the heat conductivity of water or, equivalently, the cell suspension itself. In such situation it is important to choose the proper geometry of the flow channel so that heat transfer is accomplished in the most 15 efficient way. A straight-forward derivation of the necessary parameters of an optimal design are shown below.

From the analysis of the heat flow equation:

$$Q = kA \frac{\Delta T}{\Delta x} t$$

where k is thermal conductivity of water [$0.0061 \text{ W K}^{-1} \text{ cm}^{-1}$]

20 A is surface area of one electrode

ΔT is the difference in temperature between the buffer and cooler

25 Δx is distance the heat has to travel inside the channel (one-half of the channel width, since the temperature of buffer is highest in the center of the channel or electroporation chamber) one can derive an important parameter called the thermal resistance Θ of the flow cell:

$$\Theta = \Delta T \frac{t}{Q} = \frac{\Delta x}{kA} = \frac{1}{2} \frac{w}{kA}$$

where w is the gap between electrodes.

This expression shows that thermal resistance is proportional to the width of a flow channel (the distance between 5 electrodes) and inversely proportional to the area of an electrode. The lower the thermal resistance is the more efficient is the cooling, because heat has to travel lower distance and bigger area of contact with metal is available for its transfer.

Thermal resistance shows how large the temperature 10 increase of a physical body will be if there is a continuous process of heat production within this body at the rate P . For example, if the thermal resistance is 10 degrees per Watt, one can state that the average temperature of the buffer will be 50 degrees above ambient (room temperature) if the power consumption in a continuous 15 process is 5 Watts.

Normally one would want the temperature increase to be below 20 degrees because the cell suspension is subjected to electroporation at room temperature, what makes $20+20=40$ degrees Celsius – even slightly more than the maximal temperature found in 20 living beings. It is known that proteins denature at the temperatures as high as 50-60 degrees, so the choice of 40 degrees maximum for biological applications should be quite right. On the other end, the cooler temperature cannot be lower than 0°C, or freezing will occur. Therefore, the entire practical range of temperatures that the 25 suspension of cells can be exposed to is 0 to 40 degrees.

With this limitation in mind, one can calculate the maximal power rating of any flow electroporation chamber from its dimensions:

$$5 \quad P_{\max} = \frac{\Delta T}{\Theta} \quad \text{or} \quad P_{\max} = \frac{40 \cdot 2 \cdot k \cdot A}{w} \approx \frac{1}{2} \frac{A}{w}$$

If both A and w are measured in centimeters, P_{\max} is expressed in Watts. The value of ΔT value may vary depending on the temperature of electrodes: $0^{\circ}\text{C} < \Delta T < 40^{\circ}\text{C}$.

10 The power rating allows deciding whether the geometry of electroporation chamber is optimal for required heat transfer. For example, in a continuous process where cell suspension is being electroporated at a given electric field strength and certain volume of this suspension must be processed in a given time, one can calculate
 15 the power consumption rate:

$$P = <VI>, \text{ where}$$

V is actual voltage being applied to electrodes,
 20 I is current flowing through the buffer,
 and angle brackets mean averaging over one-second interval;
 If P (power consumption) is found to be higher than P_{\max} (flow-cell power rating), the conditions for optimal heat transfer are not satisfied. In this case either the process has to be slowed
 25 down to produce less heat, or a different flow cell must be used which has a higher ratio of electrode area to the distance between

electrodes. According to the present invention, the dimensions of the electrodes, area of their contact with suspension, and the distance between the electrodes is chosen to ensure that the thermal resistance of the entire flow channel is less than approximately 3°C per Watt.

5 It is to be understood that the flow electroporation system of the present invention can be used in conjunction with commercially available cell separation apparatus. These include, but are not limited to, Haemonetics Cell Save® 5 autologous blood recovery system, the Haemonetics OrthoPAT® System, the
10 Haemonetics MCS®+ Apheresis System, the Cobe Spectra Apheresis System, the Trima™ Automated Blood Component Collection System, the Gambro BCT System, and the Baxter Healthcare CS-3000 Plus blood cell separator. The flow electroporation system of the present invention can be in direct
15 communication with these commercially available cell separation apparatus so that the cells that are isolated can be introduced into the flow electroporation system of the present invention and treated as desired.

20 Example I

Electroporation of red blood cells with IHP

It has been determined that one of the most important parameters to control is production of heat. Red blood cells are extremely sensitive to heat and this was found to be an important
25 parameter in the inefficiency of prior art electroporation methods. The following example was performed using the apparatus described herein.

60 mLs of blood is collected from a human donor into a collection set containing 15 to 20 mL of CPDA-1 (21 CFR 640.4) buffer 26.3 g trisodium citrate 3.27 g citric acid: 31.9 g dextrose: 2.22 g monobasic sod phosphate: 0.275 g adenine: H₂O to 5 1000 mL. The volume per 100 mL of blood is 14 mL))It is to be understood that larger volumes of blood can be treated with the present invention. The blood is transferred to two 50 mL centrifuge tubes and then is centrifuged for 10 minutes at 2000 g. The plasma is collected from above the cell pellets and transferred into a separate 10 sterile 50 mL tubes and stored. The buffy coat is removed from the top of the cell pellets using a plastic transfer pipette. The cells are then resuspended in 50 mLs of sterile phosphate buffered saline by gently inverting the tubes. The resuspended cells are centrifuged at 2000 g for 5 minutes. The supernatant is discarded and the 15 resuspension/centrifugation procedure is repeated. The red blood cells are then resuspended in 45 mLs of electroporation buffer. The electroporation buffer is 35 mM Na6-IHP (EntreMed, Rockville Md,), 60 mM KCl, and 10 mM D-glucose. The cell suspension is centrifuged at 2000 g for 5 minutes. The volume of the red blood 20 cell pellet is estimated visually and approximately 1.5 times the volume of the pellet of electroporation buffer is added to the cells. The cells are resuspended in the electroporation buffer by gently inverting the tubes. Insert syringe ports onto cell suspension bags (Baxter Transfer Packs, Baxter Healthcare, Chicago IL) clamp tubing 25 onto the bags with hemostats. Transfer the cell suspensions from both tubes into the first bag using 30 mL syringes and plastic needles. After the last injection of cells, pull out 15 mLs of

suspension and dispense the cells into a separate 50 mL tube for control. The second bag is filled with 30 mLs of electroporation buffer. Install a disposable set on the flow electroporation device (described above). Matching the bag and valve numbers, the tubing 5 is inserted into the four pinch valves and the appropriate part of the harness on the peristaltic pump is installed. The pump key and compression plate is closed.

The computer software is then initialized and the hemostats are removed from the bags. The pump is primed by 10 clicking on the “prime start” button on the GUI. The pump is started by clicking on the “pump on” button on the GUI. This begins the electroporation process. When the blood flow reaches the waste bag, the stream is switched so the sample is collected in the product bag by clicking the “sample start” button. The pulsing schedule with 15 preferred ranges is as follows in Table 6:

Table 6

Parameter	Preferred value	Range of values
Pulse width	650 μ s	200 to 900 μ s
Interval between pulses	100 μ s	25 to 400 μ s*
Pulses in burst	2	1 to 6
Time between bursts	12000ms	1000 to 20000
Bursts/cell	2	1 to 5

20 * The interval between bursts is dependent on the flow rate and the volume of the flow cell.

When the bag containing the blood is empty, the pulsing is stopped by clicking the “off” button on the GUI. The bag with the

treated blood is then placed into a sealable plastic overwrap (a ZIPLOC baggie) and put into a water bath at 37°C for 45 minutes. The bag tubing is then aseptically cut and the sample is divided into two 50 mL centrifuge tubes. 7.5 mLs of the cell suspension from 5 each tube is transferred to a separate 50 mL tube for testing. The remaining cell suspension is centrifuged at 2000 g for 5 minutes. The cells are washed 3 times by centrifugation in sterile PBS with 60 mM mannitol. It has been found that mannitol is important in the wash buffer and stabilizes the cell membrane better than other 10 compounds. Other polyhydroxyl hydrocarbons can be used in the present invention to stabilize the cell membrane. The concentration of mannitol is preferably between 30 mM and 90mM, a more desirable concentration of between 40 and 80 mM with the most desirable concentratn of between 50 and 7 mM. The red blood cell 15 volume is estimated visually and 1.5 times the volume of the pellet of the stored plasma is added to each tube. The red blood cells are resuspended by inverting the tubes. The right shift of the oxygen hemoglobin curve is measured in the treated cells and the untreated cells using an Oximeter. Saturation of hemoglobin with oxygen 20 (sO₂) was measured after the incubation step in both control and electroporated red blood cell samples with a CO-Oximeter™ Model 682 (Instrumentation Laboratory). Each sample was divided into three fractions, which were equilibrated for 20 minutes at 37 °C with three gas mixtures in an EQUIILibrator™ tonometer (RNA Medical). 25 The gas mixtures were obtained from RNA Medical and contained 9%, 6% and 3% oxygen, plus 5.6%, 2.8% and 1.4% CO₂, respectively, and were balanced with nitrogen. The partial pressure

of oxygen (pO₂) in each fraction and the buffer pH were measured by a model 1640 pH/BloodGas/Electrolytes device (Instrumentation Laboratory). Viability is measured by measuring free hemoglobin. The results of electroporation of several different samples of blood 5 from different doners are shown in Fig. 18. The average red blood cell loss during the entire electroporation process was between 6 and 10%.

Example 2

10 *To electroporate non-stimulated lymphocyte*

Primary lymphocytes were suspended in B&K buffer (125 mM KCl, 15 mM NaCl, 1.2 mM MgCl₂, 3 mM glucose, 25 mM Hepes, pH 7.4) cell concentration was set from 1x10⁷ cells/mL to 6x10⁸ cells/mL together with DNA plasmid from 50 µg/mL to 1 15 mg/mL. Electroporation, 2.3 kV/cm, 400 µs, 4 pulses for small volume experiments (15 µL) or 2.2 kV/cm, 1.6 ms, 1 pulse for large volume experiments (0.5mL - 2mL) was performed at room temperature. Following electroporation, cells were incubated in B&K buffer for 20 min at 37°C for small volume experiments, or diluted 20 by 10X volume of culture medium (RPMI-1640 + 10% fetal bovine serum + 1% Pen-strep + 2 mM L-glutamine) for large volume experiments. Cells were cultured in culture medium for various periods (up to 72 hours) and the transfection efficiency was analyzed.

25 Primary quiescence lymphocytes have been shown refractory to retrovirus based gene transfer. HIV based vector could transduce primary lymphocytes, but the efficiency is extremely low

in the absence of HIV accessory genes. Other non-viral transfection methods also gave very low transfection efficiency. This is the first demonstration of high efficiency of transfection of primary lymphocytes by a non-viral method.

5

Example 3

Electroporation of stimulated lymphocytes

Primary lymphocytes (5×10^6 cells/mL) were stimulated with PHA-P (up to 10 μ g/mL) and 10 U/mL hrIL-2 for 48 hours in culture medium (RPMI-1640 + 10% Fetal bovine serum + 1% Pen-strep + 2 mM L-glutamine). Large cell aggregates were collected by incubating the cells in a 15 mL centrifuge tube for 10 min in the incubator and re-suspended in B&K buffer with 200 μ g/mL of plasmid DNA. Following electroporation at 1.8 kV/cm, 400 μ s, 4 pulses, cells were incubated for 20 min in B&K buffer at 37°C for small volume experiments or diluted with 10X volume of culture medium containing 20 U/mL hr IL-2. Cells were cultured with culture medium containing 20 U/mL IL-2 for various periods (up to 20 days) and the transfection efficiency was analyzed.

20

This is the first demonstration of gene transfer of large amount of (greater than 1×10^8 cells) stimulated-lymphocytes by a non-viral method.

Example 4

Transfection efficiency analysis

Seven transgenes (Ds-Red, eGFP, β Gal, hEndostatin, hEPO, hIFN α , hIL-2) were tested in these experiments.

As used herein, a transgene is any gene that codes for a protein that is transferred into a cell. Ds-Red is under the control of CMV promoter, and is from ClonTech., eGFP is under the control of CMV early promoter with an intron, backbone is from Promega, β Gal is under the control of CMV promoter, and is from Clontech. hEndostatin is under the control of CMV promoter, and the backbone is from Invitrogen (pcDNA3.1). hEPO, hIFN α and IL2 is under the control of CMV promoter and an intron. The backbone is from Promega. When pCMV-Ds-Red or pCMV-EGFP was used, the percentage of the fluorescent cells was counted, by FACS or by manual counting under phase contrast and fluorescence microscope, as the transfection efficiency. When pCMV- β Gal was used, the percentage of stained cells (blue cells) by *in-situ* staining with X-gal was used as the transfection efficiency. When pCMV-Endostatin was used, the Endostatin concentration in the supernatant was analyzed by ELISA kit from Cytimmune Sciences, Inc. (College Park, MD). For pCMV-EPO electroporation, the erythropoietin concentration in the supernatant was analyzed by R&D ELISA kit (Minneapolis, MN). The results of the transfection efficiency analysis are summarized in Table 7 below.

Table 7. Summary of Transgene Efficiencies

Transgene	Cell Line	Viability	Efficiency (either by % of + cells or secretion level)
Ds-Red	resting Lymphocytes	50%	30%
eGFP	resting Lymphocytes	60%	50%
	stimulated Lymphocytes	50%	40%
	CHO	85%	80%
	NIH 3T3	85%	70%
	10T 1/2 fibroblast	85%	75%
	Huh-7	90%	80%
	Jurkat cells	85%	70%
βGal	resting lymphocytes	40%	15%
hEndostatin	resting lymphocytes	50%	10ng/million cells/24hr
	Stimulated lymphocytes	40%	30ng/million cells/24hr
hIFN α	stimulated lymphocytes	40%	20ng/million cells/24hr
hIL-2	Jurkat cells	60%	2500pg/million cells/24hr
hEPO	stimulated lymphocytes	45%	200ng/million cells/24hr
	NIH 3T3 cells	80%	3000ng/million cells/24hr

5 Example 5

Application of the present invention in ex vivo gene therapy

Genes encoding therapeutic proteins can be incorporated into a patient's autologous cells by the flow electroporation system of the present invention. Human erythropoietin (hEPO) was used as a marker gene to demonstrate the concept of the *ex vivo* gene therapy process. Mouse NIH3T3 cells were used as gene delivery vehicles, but in real life setting, any human primary cells can be employed into the system, such as T lymphocytes, stem cells, fibroblast, myoblast, and pancreatic cells.

10 The human erythropoietin (hEPO) gene was RT-PCR

amplified from polyA+ human kidney RNA (Clontech, Palo Alto, CA) using synthetic oligonucleotides upstream primer 5'-
CTCGAGATGGGGTGACGAATGTCCTGCC and downstream
primer 5'GTCGACTCATCTGCCCCGTGCAGGC and
5 cloned into pCR2.1-TOPO (Invitrogen, Carlsbad, CA). Then the
coding region for hEPO was excised by EcoRI and cloned into the
mammalian expression plasmid pTM4 to construct pTM7 (CM V-
hEPO-IRES-eGFP).

Plasmid pTM7 was propagated and band purified twice
10 by CsCl gradient. Endotoxin level was < 3EU/mg. Purified plasmid
was re-suspended in endotoxin free H₂O and stored at -20⁰C.

NIH3T3 mouse fibroblast was cultured according
ATCC guidelines and re-suspended in B&K pulsing buffer (125 mM
KCl, 15 mM NaCl, 1.2 mM MgCl₂, 25mM Hepes, 3 mM Glucose,
15 pH 7.4) and transfected with pTM7 (100 µg/mL) using the flow
electroporation system of the present invention: 2.1 KV/cm, 400 µs,
4 pulses at 1.25 sec interval, and flowing at 0.1 mL/s. Then the
fibroblasts were incubated in the pulsing medium for 20 min before
injected into SCID mouse. Flow analysis revealed that about 75% of
20 cell population expressed eGFP.

Each SCID mouse was SQ injected with 2x10⁶ hEPO
transfected cells. Control group was injected with non-transfected
cells. Mice were bled 5 days, 12 days, 19 days, 26 days post
injection. The blood was collected by heparinized capillary tube.
25 Hematocrit was measured by the volume of red blood cells over the
whole blood volume. The results of this series of experiments is
shown in Fig. 19.

Example 6

Application of the flow electroporation system of the present invention in drug target discovery

5 Incorporation of targeted molecular beacons (MB) is very effective for real-timing new drug target screening. The MB was an anti-sense DNA oligo labeled with fluorescence at one end, and with quenched molecule at the other end. When the MB enters a live cell that express this target, the MB anti-sense DNA will bind to
10 the target and the fluorescenced MB will be dequenched and light up the cells.

Human β -actin is used as an example, scrambled actin MB as negative control. Jurkat cells are re-suspended in B&K medium, pH 7.4, (125 mM KCl, 15 mM NaCl, 3 mM Glucose, 15 25mM Hepes, 0.5 mM MgCl₂). The cells are electroporated four times with 1 kV/cm, 400 μ sec/pulse at 1 second between pulses. Then cells are incubation at 37°C for 20 minutes. Before FACS, cells are washed twice in PBS. About 1 hour post electroporation, cells are analyzed by flow cytometry. In Fig. 20, electroporation
20 mediated DNA oligo uptake by mammalian cells is shown. Uptake is DNA oligo concentration dependent. Uptake efficiency is over 88%, while viability is approximately 90%. Fig. 21 shows a fluorescence difference when β -actin (blue) or scrambled DNA (orange) MBs were incorporated into Jurkat cells by electroporation. This suggests
25 that β -actin is expressed and positively recognized by its anti-sense MB. Thus, an RNA expression profile of cells being treated with a known drug can be obtained and used as a template to screen for

other unknown drugs. Using this method, many new drugs or compounds can be identified and replace current treatments.

Example 7

5 *Application of the flow electroporation system of the present invention in viral vector production*

Retroviruses are currently the most widely used vectors in clinic trials for gene therapy. Only adherent cells lines have been used for the generation of packaging cells for the production.

10 Recently, Chan et al., and Pizzato et al. reported stable suspension producer cell lines derived from human lymphoblastic cells (Gene Ther 2001 May) providing proof-of-principle that production of high titre virus can benefit from suspension cells. However, large-scale production of pseudotyping retrovirus and lentivirus remains

15 unsolved. Current protocol for production of pseudotyping retrovirus and lentivirus involves transient co-transfection of adherent cells with 3 or 4 plasmids, which is limited by low titers partly due to the restrictive nature of monolayer cell culture and low transfection efficiency.

20 Cultured CHO cells were trypsinized and re-suspended in B&K buffer pH7.4, (125 mM KCl, 15 mM NaCl, 3 mM Glucose, 25mM Hepes, 0.5 mM MgCl). Then plasmid 1 (pCMV-Ds-Red), and plasmid 2 (pCMV-intron-eGFP) were added in the cell suspension at 200 µg/mL. The cell-DNA mixture was introduced into the flow

25 electroporation system. FACS was conducted 48 hours post electroporation. As shown in Fig. 22, more than 85% of the cell population expressed eGFP, while 44% of the cells expressed Ds-

Red. Viability of the cells was >90%. The difference between these two transgene expressions may due to the fact that green fluorescence is more sensitive than red fluorescence, and that eGFP was driven by CMV-intron, which has been shown more efficient
5 than CMV alone.

Current lentiviral vector production involves transient co-transfected cells with either 2 or 3 different plasmids to make “safe” viral vector. Small scale viral production can be processed by CaPO₄ transfection methods, but production for clinical applications
10 is not possible using this production method. The flow electroporation system of the present invention system provides state-of-art technique for vector production. More than 20 mL of cells at 200 x 10⁸ cells/mL can be transfected with the flow electroporation system of the present invention system (in all, 4 x 10⁹
15 cells) in less than 1 hr.

Example 8

Platelets migrate to disrupted vascular sites because their membrane contains receptors for proteins that are found there (e.g.,
20 fibrin and collagen). These proteins are also found at sites of infection and metastasis – if otherwise toxic drugs can be inserted into platelets, the platelet can be utilized as a drug delivery system (an “intelligent liposome.”)

Results are shown in Table 8. Efficacy is expressed as
25 the percentage of cells that took up fluorescent markers (calcein or albumin + fluorescein). “Activity” was determined by measuring biologic functions, such as secretion or aggregation (for MaxCyte’s

application, any detectable level will probably suffice). "Survival" is the circulating half-life in an animal model.

Table 8. Platelet: Laboratory Results

5

	Efficacy (% of cells with marker)	Activity (% of control)	Survival (% of control)	Processing Rate (cells/min)
Human platelets CALCEIN	80+	40 - 60	30 - 40	1 to 2 billion

Platelets are primarily known as components of the haemostatic mechanisms and, in that role, traffic to sites of vascular injury to form an aggregate with coagulation factors and to stop 10 vascular leakage. Targeting is accomplished via the biological properties of the platelets themselves. Specialized molecules on the platelet surface (receptors) specifically interact with proteins found not only at areas of vascular damage, but also at sites of infection, metastasis, and inflammation. The target proteins include 15 fibrinogen, collagen, von Willebrand Factor (vWF), and adhesion proteins such as ICAM-1.

The concept that a biologically active agent can be inserted into platelets with electroporation and that the agent will then exert an effect at a target site has been demonstrated and is 20 documented in peer-reviewed literature. In these cited studies, platelets were treated with static systems that accommodated a maximum of 0.5 mL of cell suspension. The MaxCyte system

permits processing of tens or hundreds of milliliters of cell suspension with a rapid (minutes) throughput time.

Figure 23 shows scatter plots from a flow cytometer. Control (23A) was incubated in a dilute solution of the fluorescent 5 dye, calcein, for approximately 1 hour. The test sample (23B) was suspended in the same dye solution, but was run through the electroporation device. Similar results were obtained using fluoresceinated albumin.

10 Example 9

Platelets were treated with the MaxCyte System in the presence of a marker dye, calcein, then stimulated with increasing doses of collagen, a physiologic stimulant for platelets. This study demonstrated that the platelets retain biologic function, as 15 demonstrated by the secretion of beta-thromboglobulin, a protein contained within platelets that is normally released upon activation. The detection of any level of activity indicates that the platelets are viable after the processing. On the other hand, the platelets do not release the molecular marker (calcein) that was loaded into them. 20 This indicates that platelets loaded with a therapeutic agent would not prematurely release their “cargo”, but would retain it until the loaded platelet adhered to a biologically active site and underwent degradation over a period of days (which is the expected behavior for platelets). 25 These experiments indicate that the loaded material is in the cell cytosol and not in the granules. Observation of platelets, loaded with the dye alexa, by confocal microscopy confirms that the dye is

located diffusely within the platelet and is not simply adherent to the membrane.

Figure 24 shows platelets that had been washed but otherwise not treated (Untreated[NT]), platelets that were incubated with the 5 fluorescent marker calcein (calcein control) and platelets electroporated with calcein (electroporated) were subsequently stimulated with the physiologic stimulus, collagen. 24(A): Samples responded similarly to a collagen stimulus by releasing beta-thromboglobulin, a natural constituent of platelets. 24(B): Platelets 10 do not release the dye when stimulated.

Example 10

Studies were performed with human platelets in a rabbit model, in which the animals were pre-treated with an agent that 15 blocked macrophage activity. Platelets loaded with calcein or albumin circulate, but with a half-life less than that of untreated control platelets (Control 8 hours, test 2.5 – 3 hours). These studies show that platelets clearly have a finite circulation.

20 Example 11

In another series of studies, platelets loaded with calcein were infused into the rabbits and major organs harvested within 1 half life. Platelets were found in multiple organs – heart, intestine, muscle kidneys, liver and spleen. These studies demonstrate that 25 platelets distribute to heart, kidneys, gut, etc., and are not simply sequestered in liver and spleen, as is the case with liposomes.

Example 12

Mouse IL-12 transfected cells in a MatriGel model was examined. mIL-12 has been shown to up-regulate IFNy and IP10, and to block angiogenesis. Mouse embryonic fibroblast 10T1/2 cells 5 were transfected with a DNA plasmid encoding mIL-12 and injected subcutaneously into C3H mice. Human recombinant bFGF was mixed with MatriGel and subcutaneously injected at a remote site from the one of transfected cells injection. In one group of mice, the transfected cells were mixed together with bFGF and MatriGel. The 10 amount of hemoglobin in MatriGel was analyzed 6 days post injection, and served as an indicator of angiogenesis. Data (Figure 24) showed that mIL-12 transfected cells inhibited angiogenesis more than 70%. The transfected cells secreted about 72 ng of mIL-12 (1x10⁶ cells in 24 hrs). Systemic mIL-12 level was elevated 15 among mice received mIL-12 transfected cells injection. No cytotoxic effect was observed. These results suggest that MaxCyte system-mediated high-flow transfected cells are viable and express functional gene product *in vitro* & *in vivo*.

Thirty min post transfection, mIL-12 modified mouse 20 embryonic 10T1/2 cells were subcutaneously injected into C3H mice. Matrigel with 1 g/mL bFGF was subcutaneously injected into dorsal thorax area, mixed or not mixed with cells. Control represents mice injected with non-transfected cells. Cells were injected on ventral side close to thigh. ELISA analysis (R&D System) revealed 25 up to 80-100 pg/mL of mIL-12 in treated mice plasma 2 days post injection.

mIL-12 transfected mouse embryonic fibroblast blocked bFGF induced angiogenesis (Figure 25). The MatriGel plugs were removed from the mice described in the previous figure, and homogenized in 1 mL of PBS. The hemoglobin amount was analyzed 5 by absorption at 415 nm. Local delivery of mIL-12 transfected cells (in MatriGel) resulted in 70% of inhibition of angiogenesis.

The terms and expressions which have been employed herein are used as terms of description and not of limitation, and there is no intention, in the use of such terms and expressions, of 10 excluding any equivalents of the features shown and described or portions thereof. Having thus described the invention in detail, it should be apparent that various modifications can be made in the present invention without departing from the spirit and scope of the following claims.

15